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The Foot-and-mouth disease virus (FMDV) affects cloven-hoofed animals and is endemic in 
most parts of Africa, South America and southern Asia. South Africa is considered a FMDV-
free zone but the virus is maintained within the wildlife in the Kruger National Park (KNP), 
making mitigation of outbreaks a high priority. Diagnostic methods are usually costly due to 
the high production cost of the reagents used, meaning that regular monitoring and diagnosis 
of animals around the KNP for FMDV is expensive due to the large amounts of serum 
continuously being tested. I propose an alternative plant expression platform for the local 
production of more cost effective diagnostic reagents capable of distinguishing between 
infected and vaccinated animals (DIVA). I selected the non-structural 3ABC polyprotein of 
FMDV to express, as it is a suitable candidate as a coating antigen in a competitive enzyme 
linked immunosorbent assay (C-ELISA) for the detection of neutralizing antibodies in livestock 
sera. I also chose other variations of the full polyprotein (3AB, 3AB1 and 3B) for expression as 
they have previously been shown to be effective in FMDV diagnosis. I also selected a second 
reagent to be expressed: this was the CRAb-FM27 single chain variable fragment (scFv), which 
binds a 3B epitope on the 3ABC polyprotein and has previously shown to be effective as a 
competing antibody in a C-ELISA. The 3B antigen and the scFv were successfully expressed 
and purified from N. benthamiana, which to my knowledge is the first time either has been 
shown. The plant produced scFv successfully bound the 3B antigen in an Indirect-ELISA (I-
ELISA). Separately, the plant produced 3B antigen could be used to successfully differentiate 
FMDV infected and vaccinated guinea pig serum in an I-ELISA. However, testing of these 
reagents in tandem within a C-ELISA to DIVA sera was inconclusive, and further research is 
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LITERATURE REVIEW  
1.1 GENERAL INTRODUCTION 
The Foot-and-mouth disease virus (FMDV) causes a highly contagious acute infection that 
affects cloven-hoofed animals (order: Artiodactyla). The virus is often linked to livestock 
infection – that is, cattle, sheep, goats (ruminants) and pigs - but is also known to infect over 
70 species of wildlife (Alexandersen and Mowat, 2005). The virus causes Foot-and-mouth 
disease (FMD) which is categorised as a list A disease, that has the ability to spread rapidly 
and potentially cause serious economic and agricultural loss (Stear, 2005).The strain put on a 
country during an outbreak can be devastating, even with the virus usually only having a 
short-term effect on the animal. The visible production losses include reduction in milk by 
about 80% (Bayissa et al., 2011) and young animal mortality rates of 2-3% (Rufael et al., 2008). 
The invisible losses due to FMD are abortions, where farmers must decide to keep the animal 
for up to a year without production or cull it. As a direct impact, nations without FMD-free 
status cannot trade live animals with FMD-free countries, and restrictions are made with 
regards to livestock products. This cut-off to a lucrative market that some countries depend 
heavily upon, can have compounding negative effects on their economies (Knight-Jones and 
Rushton, 2013). 
The aggressive nature of the virus is exemplified by its ability to spread quickly through direct 
and indirect methods. The most common form of transmission is through direct contact with 
infected animals. The virus is known to have been recovered in most bodily excretions (milk, 
saliva, semen, urine and faeces) and the primary mechanism of spread is through the 
inhalation of aerosolised droplets into the respiratory tract. Indirect contact with 
contaminated personal, surfaces and foods have also shown to be responsible for 
transmission (Alexandersen and Mowat, 2005; Klein, 2009; Admassu et al., 2015). 
The incubation period of the virus can vary depending on viral dose, route of transmission 
and the animal species being infected (Alexandersen, Zhang, et al, 2003). This ranges from 2-
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14 days and at the end of this time frame, ample amounts of virus can be shed and 
disseminated. The early clinical signs include fever, extensive salivation, depression and 
lameness, which are then followed by the formation of vesicular lesions around the mouth, 
muzzle, udder and feet. The inability to walk and eat is a result of the lesions and contributes 
to weight loss (Alexandersen, Quan, et al., 2003; Alexandersen, Zhang, et al., 2003; 
Alexandersen and Mowat, 2005; Admassu et al., 2015).  
The disease is controlled by restricting trade of livestock and animal products from known 
FMD endemic countries. Countries are classed into FMDV-free with or without vaccination, 
depending on their current prevention procedures. During an emergency outbreak within a 
FMDV-free country, “stamping-out” procedures are deployed. The world organization for 
animal health (Oficina Internacional de Epizootias, OIE) defines it as, the slaughter and 
disposal of all infected and in-contact animals, the disinfection and cleaning of all equipment, 
and restricting movement of animals and personal (OIE, 2016). In contrast, countries where 
FMD is endemic, prophylactic vaccinations and limitation of animal movement are employed 
to protect high yielding livestock (Admassu et al., 2015). The highly infectious nature of the 
virus and the ease with which it can spread amongst a population of livestock and wildlife 
animals, shows the importance of control and prevention. The first line of defence in this case 
is to have a well-established, rapid and accurate method of diagnosis. The combination of 
continuous systematic inspection of clinical signs and virological and serological diagnosis are 
currently used and have been shown to be highly successful in combatting outbreaks. 
1.2 VIRAL CLASSIFICATION AND GEOGRAPHICAL DISTRIBUTION 
FMDV is classified within the Aphthovirus genus as a member of the Picornaviridae family 
(Belsham, 1993) of small non-enveloped isometric ssRNA-containing viruses. There are seven 
serotypes of the virus, each consisting of varying subtypes distributed around the world. The 
O and A types are the most widely distributed, appearing in many parts of Africa, South 
America, southern Asia and the Far East. Type C occurs in the Indian sub-continent and the 
Asia 1 serotype in southern Asia, to where these serotypes have become confined. The SAT 
serotypes (SAT1, SAT2 and SAT3) are usually restricted to sub-Saharan Africa. Central and 
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North America, Europe and Australasia are amongst the few that are FMDV-free. (Knowles 
and Samuel, 2003). Figure 1.1 shows the distribution of the seven serotypes.  
 
Figure 1.1. Distribution of the seven serotypes globally.  
Reported to the OIE from 1990-2002. Taken and adapted from Grubman and Baxt (2004). 
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1.3 VIRAL COMPONENTS 
The FMDV genome consists of single-stranded plus-sense RNA, which is approximately 8500 
nucleotides in length, enclosed by four structural proteins to form a non-enveloped 
icosahedral capsid (Crowther, 1986; Sobrino et al., 2001; Grubman and Baxt, 2004). The 
genome is flanked by 5’ and 3’ untranslated regions (UTRs), which do not encode viral proteins 
but show complex secondary structure involved in viron replication and translation. A single 
open reading frame (ORF) is encoded between the UTRs that translates into a single 
polyprotein, which undergoes multiple post-translational proteolytic cleavages to produce 
both intermediate and mature structural and non-structural proteins (NSPs) (Mason, 
Grubman and Baxt, 2003; Grubman and Baxt, 2004). A representation of the viral genome is 
shown in Figure 1.2. 
1.3.1 THE 5’ UNTRANSLATED REGION 
The 5’ UTR is about 1300 bases in length and is divided into five functional elements that are 
involved in virus translation and RNA replication. These are the S fragment, the poly(C) tract, 
the pseudoknots, the cis-acting replication element, and the internal ribosome entry site 
(IRES). The 5’ terminus is covalently bound to a genome-linked protein (VPg), encoded by the 
3B region, which is important for initiation of RNA synthesis and viral RNA encapsulation 
(Belsham, 1993; Mason, Grubman and Baxt, 2003). The 5’ UTR elements are well described 
by Mason et al. (2003). 
1.3.2 THE POLYPROTEIN 
The long polyprotein encoded between the 5’ and 3’ UTRs is divided into four protein regions 
(Figure 1.2). These are the L protease (Lpro), P1 (precursor of the structural capsid proteins), 
P2 and P3 which produce a range of non-structural proteins involved in viral replication. 
Processing of these four regions is achieved through the action of viral encoded proteases 




1.3.2.1 Proteases  
 The 5’ terminus of the ORF contains two in-frame start codons (AUG), which encode the Lab 
(major protein) and Lb leader proteases (Lpro) (Robertson et al., 1985; Sangar et al., 1987). The 
Lpro cleaves itself from the C-terminus of the polypeptide chain and is responsible for the 
cleavage of the host cell protein, eukaryotic initiation factor (eIF-4G). This results in the shut-
down of the host cap-dependent mRNA translation and subsequent ceasing of host protein 
Figure 1.2. Schematic diagram of the FMDV genome. 
The protein-encoding region or ORF is indicated by the open boxes and the lines either side indicate the RNA UTR’s. The 
proteins are named according to the L434 convention with the nomenclature of Rueckert and Wimmer (1984) 
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synthesis. As the FMDV RNA initiates translation in a cap-independent manner via its IRES, 
viral protein synthesis is uninhibited (Devaney et al., 1988). 
One of the most versatile viral encoded proteases is the 3C protease (3Cpro), as it is responsible 
for the majority of polyprotein processing by proteolytic cleavage (Vakharia et al., 1987; 
Clarke and Sangar, 1988). The 3Cpro has also been shown to cleave eIF-4G but at different 
locations to that of Lpro. It also cleaves the host RNA helicase (eIF-4A), a component of the 
cap-binding complex (Belsham, McInerney and Ross-Smith, 2000). It has also shown 
proteolytic activity towards host H3 histone (Falk et al., 1990) and  therefore not only inhibits 
host translation, but plays an important role in host transcription shut-down.  
The P2 region of the polyprotein encodes the 2A peptide which is involved in the autocatalytic 
cleavage between the 2A-2B junction. This ‘autoprotease’, which is 18 amino acids in length, 
separates itself from the 2BC-P3 polyprotein, forming the P1-2A precursor. (Donnelly et al., 
2001). 
1.3.2.2 Structural proteins 
The P1 region of the viral genome encodes for the structural proteins (Figure 1.2), with the 
P1-2A precursor being catalytically cleaved by 3Cpro into the VP0, VP3 and VP1 proteins that 
assemble into single protomers. The icosahedral capsid (Figure 1.2) consists of 60 protomers, 
five of which assemble into a pentamer and twelve pentamers into the full 28-30nm 
icosahedral capsid (Sobrino et al., 2001). 
1.3.2.3 Non-structural proteins 
The non-structural proteins arise from the P2 and P3 region of the viral polyprotein (Figure 
1.2). They are involved in genome replication and participate in structural protein folding and 
assembly. The P2 polyprotein is autocatalytically processed by 2A, resulting in the 2BC 
polyprotein, which is further processed by 3Cpro into mature 2B and 2C proteins. These 
proteins have been known to associate with cellular membranes as well as interfering with 




The P3 polyprotein is also processed by 3Cpro, giving rise to the 3A, 3B, 3C and 3D proteins 
(Mason, Grubman and Baxt, 2003). The 3A protein has been shown to associate with 
intracellular membranes, and is thought to anchor the replication complex of picornavirus to 
the endoplasmic reticulum (ER) membrane (Weber et al., 1996; Suhy, Giddings and 
Kirkegaard, 2000; O’Donnell et al., 2001). The 3B protein consists of three highly conserved 
non-identical proteins that are involved in linking to the viral RNA at the 5’ UTR, by 
phosphodiester bonds (Forss and Schaller, 1982). These viral-genome linked proteins are 
involved in RNA synthesis and encapsulation, and their copy-number has been linked to host 
range and pathogenic potential of FMDV (Falk, Sobrino and Beck, 1992; Pacheco et al., 2003). 
The 3Cpro is a serine protease and is largely involved in polyprotein processing as mentioned 
before. The 3D protein is a RNA-dependent RNA polymerase (3Dpol) (Newman et al., 1979) 
and is responsible for positive and negative-strand RNA synthesis. The 3Dpol is a major 
component of the virus infection-associated antigen (VIAA), and has shown as an indicator of 
infection (Cowan and Graves, 1966) as its presence would indicate viral replication. 
1.3.3 THE 3’ UNTRANSLATED REGION 
The FMDV genome contains a poly(A) tract at the 3’-end which is thought to be involved in 
processes required for polyadenylated mRNAs, as well as circularization of the RNA genome 
as a mechanism for positive strand replication (Herold and Andino, 2001; Mason, Grubman 
and Baxt, 2003). The 3’ UTR is thought to have cis-acting sequences required for the initiation 
of genome replication, but it is still poorly understood (Mason, Grubman and Baxt, 2003). 
1.4 VACCINES AND NON-STRUCTURAL PROTEINS 
The production of vaccines has been explored in depth, from the classic killed whole virion 
preparations, to the more modern alternatives of using genetically engineered attenuated 
strains. To then expressing the VP1 protein and its fragments as synthetic peptides or in 
microorganisms (Küpper, 1984; Brown, 1988), to the use of adenoviruses to express P1 for 
cattle protection (Sanz-Parra et al., 1999). The use of genetically engineered attenuated 
strains of the virus have been shown to protect cattle (McKenna et al., 1995) and progress is 
being made in making recombinant empty viral capsids (Lewis, Morgan and Grubman, 1991). 
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Conventional vaccines against FMDV consist of different serotypes of chemically inactivated 
virus. Binary ethyleneimine (BEI) is used to neutralise the virus, which is then formulated 
along with an adjuvant before it can be used. Aluminium hydroxide gel plus saponin, is used 
for ruminants. Whereas oil-based adjuvants are used for swine (Doel, 1999). The preparation 
of these vaccines requires the growth of the virus in tissue culture in high-containment 
facilities, as it is non-attenuated and still virulent. Purification of the inactivated virus using 
polyethylene glycol (PEG) and ultracentrifugation has been shown to be successful. 
Depending on the procedure used by the manufacturer, variable levels of non-structural 
proteins will be present as a result of the growth cycle of the virus in tissue culture (Wagner, 
Card and Cowan, 1970; Lubroth et al., 1996; Clavijo, Wright and Kitching, 2004). The virus 
infection-associated antigen protein which includes the 3Dpol, in particular, has been shown 
to be present in vaccine preparations as it is incorporated within the virion. Therefore, 
animals vaccinated using inactivated FMDV have antibodies directed towards VIAA after 
multiple doses (O’Donnell et al., 1997).  
1.5 DIAGNOSIS OF FMDV 
The implementation of a well-established diagnostic procedure is important for early 
detection and to mitigate the spread during FMDV outbreaks. The combination of clinical 
analysis of symptoms, and virological and serological diagnosis has been shown to be most 
effective in FMDV control. This is particularly important as swine vesicular disease, vesivirus, 
vesicular stomatitis and vesicular exanthema symptoms cannot be discriminated from those 
due to FMDV infections (Alexandersen, Zhang, et al., 2003). A range of nucleic acid, antibody 
and viral antigen detection techniques have been developed in order to optimise swift and 
effective identification of the virus. Distinguishing vaccinated from infected animals (DIVA) is 
of great importance, as countries that use vaccination outbreak mitigation would need to 
differentiate their livestock to prevent any unnecessary culling.     
1.5.1 CLINICAL DIAGNOSIS 
Clinical signs of the virus follow after an incubation period of between 2-14 days, these include 
fever, lameness and lesions on the mucous membranes in and around the mouth as well as 
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on the feet and around the mammary glands (Admassu et al., 2015). These debilitating 
symptoms have an effect on milk production, weight loss and although the mortality rate is 
low in adults, the virus affects the hearts of developing young which leads to increased 
mortality due to necrotizing myocarditis (Grubman and Baxt, 2004). In sheep, goats and deer, 
these lesions are not as noticeable, therefore making it difficult to identify infected animals 
and making them a dangerous source of infection. The diagnosis from clinical signs become 
complex as there are a range of other viral disease that display the same symptoms, including 
swine vesicular disease and vesicular stomatitis that cause identical lesions to FMDV 
(Rémond, Kaiser and Lebreton, 2002). The severity of acute clinical signs can vary and is 
dependent on viral dose, route of transmission and the animal species being infected 
(Alexandersen, Zhang, et al., 2003). Therefore suspected infection requires laboratory 
confirmation, by the recovery of virus from epithelial tissue, blood, vesicular fluid and 
oesophageal secretions (Rémond, Kaiser and Lebreton, 2002). Recent work by Gloster et al. 
(2011), have investigated the use of thermal imaging for the early detection of FMDV by 
measuring the temperature around the hoof and eye areas. Success with this was limited 
however, as the ambient temperature and animal’s movement prior to measurement affects 
the results. Recent work has also been done on pre-clinical detection of the virus with use of 
an air filter sampling system, which has shown promise as a non-invasive screening method 
(Waters et al., 2014; Pacheco et al., 2017). Early clinical diagnosis along with virological 
diagnostics could prove to be more effective than waiting for clinical signs to appear.  
1.5.2 VIROLOGICAL DIAGNOSIS 
Identification of the viral agent involves virus isolation or reverse transcriptase-PCR (RT-PCR) 
on samples of the oesophageal-pharyngeal (OP), epithelial tissue, vesicular fluid, milk or 
blood. The use of enzyme-linked immunosorbent assay (ELISA) and complement fixation (CF) 
testing is also used in combination as an immunological diagnosis for capturing structural 
components of the virus. 
1.5.2.1 Viral isolation 
Viral isolation and characterisation has been considered to be the ‘gold standard’ for FMDV 
diagnosis. It involves the inoculation of primary cell lines (calf thyroid or pig, calf, or lamb 
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kidney) or established cell lines (BHK-21) with suspected sample suspensions. The observation 
of a cytopathic effect (CPE) indicates viral replication. This is a time consuming and expensive 
method which requires maintenance of cell lines and a facility that meets the requirements 
for containment of group 4 pathogens. The established cell lines are known to exhibit 
inconsistency in comparison to the primary cell lines and attempts at immortalising primary 
cells to reduce costs, has been shown to display less sensitivity (Ferris et al., 2002; Rémond, 
Kaiser and Lebreton, 2002). 
1.5.2.2 Immunological methods 
The complement fixation test (CFT) has been used for many years as a means of detecting 
capsid proteins of the virus from epithelial samples. This test requires serotype-specific 
antisera and is used to distinguish between different strains of FMDV (Gritsenko, Sobko and 
Chepurkina, 1975; Ferris et al., 1984). However, there are disadvantages to the CFT: 
interpretation becomes difficult due to pro- and anti-complementary activity of the samples 
and it requires propagation of the virus in cell culture if the viral titres are too low, which is 
time consuming (Ferris and Dawson, 1988; Rémond, Kaiser and Lebreton, 2002).  These 
complications have given rise to the development of an antigen capture ELISA, which is now 
the preferred method of FMD viral antigen detection and identification of serotype (Ferris 
and Donaldson, 1992; OIE, 2012). Recent developments in viral antigen detection have 
recently been made by Yang et al. (2015), with the use of a multiplex lateral flow strip test for 
a more rapid means of detection. This test has been shown to be comparable to the double 
antibody sandwich ELISA and is showing promise as a valuable tool for rapid detection and 
serotyping (Yang et al., 2015).   
1.5.2.3 Nucleic acid recognition 
The development of RT-PCR methods of FMDV diagnostics has been achieved by use of 
universal primers that are able to differentiate between serotypes (Callens and De Clercq, 
1997). The serotype-specific primers used, generally correspond to the VP1 genome coding 
region which is responsible for the antigenic diversity between groups of the virus. Primers 
were also designed to differentiate FMDV from other known enteroviruses and other viruses 
of vesicular diseases. These primers are based on the highly conserved 3Dpol coding region of 
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the FMDV genome (Meyer et al., 1991; Rodríguez et al., 1992; Callens and De Clercq, 1997). 
Recent developments have been made in order to better diagnose clinical samples of FMDV 
using RT-PCR and sequencing (McKillen et al., 2011; Le et al., 2012; Xu et al., 2013). A novel 
reverse transcription loop-mediated isothermal amplification (RT-LAMP) test has been 
developed, which has been shown to be significantly more sensitive and quicker than RT-PCR 
(Chen et al., 2011; Madhanmohan et al., 2013; Kasanga et al., 2014), which is paramount in 
diagnosing a highly infectious disease. In addition, advancements in next-generation 
sequencing have allowed for a universal protocol to be developed, which uses whole genome 
sequencing of FMDV for better diagnosis and eliminates the need for genome-specific PCR 
amplification (Logan et al., 2014). 
1.5.3 SEROLOGICAL DIAGNOSIS 
There are four main reasons for serological testing of FMDV, as stated in the OIE terrestrial 
manual of 2012. These are 1) to confirm suspected cases of FMDV; 2) to validate the absence 
of infection; 3) to prove efficacy of vaccination and; 4) to endorse animals for export or import 
(OIE, 2012). Different tests and interpretations are based on whether the animal population 
has been vaccinated or not during an outbreak, or as a means of an ongoing vaccination 
programme for mitigation. There are two types of serological testing done: those that identify 
antibodies binding to structural proteins (SP) and those that detect antibodies binding to non-
structural proteins (NSP) of the virus. 
1.5.3.1 Structural protein testing 
The advantage of using SPs as diagnostics is that they are able to detect antibodies elicited 
from different serotypes and are therefore very serotype-specific. The disadvantage is that 
the detection of antibodies to SPs does not distinguish between infected and vaccinated 
animals. Some of these tests include the virus neutralisation test (VNT) (Golding, Hedger and 
Talbot, 1976), the solid-phase competition-ELISA (SPCE) (MacKay et al., 2001; Chénard et al., 
2003; Paiba et al., 2004) and the liquid-phase blocking-ELISA (LPBE) (Hamblin, Barnett and 
Hedger, 1986; Hamblin et al., 1987). These are the OIE-prescribed tests for trade, and are 
used to confirm ongoing or previous infections in non-vaccinated animals. They are serotype-
specific but sensitivity is dependent on the virus being used in the tests matching those strains 
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in the field. The VNT is performed in tissue-culture microtitre plates and requires the use of 
BHK-21, lamb or pig kidney cells as well as live virus. Although this test is sensitive, it is also 
laborious, time consuming and needs biosafety level 3 facilities. On the other hand, the ELISA 
based tests require serotype-specific monoclonal or polyclonal antibodies, do not depend on 
tissue culture and are much quicker and correlate well with the VNT (OIE, 2012). It has been 
shown that both the SPCE and LPBE are able to detect lower levels of antibodies compared to 
the VNT but the specificity of the SPCE was higher than that of the LPBE but equivalent to that 
of the VNT (MacKay et al., 2001). 
1.5.3.2 Non-structural protein testing 
The advantage of using NSPs over SPs as a diagnostic antigen is that the presence of 
antibodies to NSPs can be used to distinguish infected from vaccinated animals. NSPs can 
detect antibodies elicited by live replicating virus but not by inactivated virus used for 
vaccinations, with the exception of the VIAA. The disadvantage is that these tests are still not 
serotype-specific and would only indicate infection of FMDV or not. Therefore these 
diagnostics are usually used for certifying animals for trade and between regions that are 
FMDV-free with vaccination (OIE, 2012). The prescribed tests are usually based on a 
combination of different formats of ELISAs and immunoblotting (Bergmann et al., 2000). 
The advancement of recombinant techniques using a range of in-vitro expression systems has 
allowed for different NSPs of the virus to be examined and for the most immunogenic to be 
identified. A variety of recombinant NSPs have been tested from both the P2 and P3 regions 
of the viral genome. The work done by Rodríguez et al. (1994) assessed the FMDV Leader, 2C, 
3A, 3B, 3C, 3AB, 3ABC and 3D NSPs for their immunogenicity in swine to determine if anti-
FMDV antibodies against these proteins were detected in infected and vaccinated animals. 
The results indicated that the 3ABC polyprotein was the most antigenic and was able to 
successfully distinguish infected from vaccinated animals (Rodríguez et al., 1994). Work done 
by Mackay et al. (1998), examined serum from infected and vaccinated cattle and confirmed 
that the 3ABC polyprotein was the most immunogenic of all the NSPs. It was also noted that 
the 3D protein gave false positive readings of infection from post-vaccinated serum of cattle 
that received less than five vaccinations, whereas the 3ABC polyprotein would not. It was only 
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after ten or more vaccinations that the other NSPs could not differentiate between infection 
and vaccination (Mackay et al., 1998). This positive correlation between increased number of 
vaccinations and the inability to distinguish infected from vaccinated animals using NSPs is 
linked to the impurity of the vaccines used, as mentioned in section 1.4.   
With the 3ABC polyprotein showing promise as a diagnostic reagent for DIVA, much work has 
been done to show its effectiveness in a range of different diagnostic tests. The 3ABC 
polyprotein has been shown to function in indirect-ELISAs (I-ELISA) (Sørensen et al., 1998; 
Srisombundit et al., 2013) and competitive-ELISAs (C-ELISA) (Sharma et al., 2012) with great 
sensitivity and specificity. With comparisons being made with other NSPs, it has again been 
confirmed that the 3ABC polyprotein is the most immunogenic. The full 3ABC polypeptide has 
also been truncated into the smaller individual NSPs (Figure 1.2) and tested in a range of 
ELISAs. The 3AB1 polypeptide has also been shown to successfully distinguish infected from 
vaccinated animals in an I-ELISA (Nanni et al., 2005; Jaworski et al., 2011). Use of the 3AB 
polypeptide has been explored in I-ELISAs (Chung et al., 2002) and shown to be just as 
effective as the 3ABC polyprotein (Sørensen et al., 1998). Much work has also been done using 
the 3B (all three copies B1B2B3) protein in an I-ELISA (Mohapatra et al., 2014), and results in 
an I-ELISA have shown comparability to three commercial diagnostic kits (Gao et al., 2012). 
The 3B protein has also been shown to be effective as a synthetic peptide in an I-ELISA (Shen 
et al., 1999).   
The OIE has adopted an I-ELISA based on the E. coli-produced 3ABC polyprotein (NSP) as its 
index screening method, developed by PANAFTOSA (Stear, 2005). This is being used to help 
discriminate between infected and vaccinated animals in countries that used emergency 
FMDV vaccines to regain their FMDV-free status. This has helped reduce the need for 
unnecessary mass slaughter of vaccinated animals (vaccinate-to-live) (Brocchi et al., 2006). 
This method of diagnosis has been used as a reference to validate other NSP diagnostic tests. 
The OIE manual of diagnostic tests and vaccines for terrestrial animals indicate the index 
screening method for PANAFTOSA to be I-ELISAs and enzyme-linked immunoelectrotransfer 
blots (EITB). It also states that C-ELISAs have equivalent diagnostic performance (Stear, 2005). 
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Investigation into the comparison between the different NSP diagnostic test kits was done, in 
order to determine which might have better DIVA capabilities. Two studies looked at 
comparing commercial kits; CHEKIT-FMD-3ABC bo-ov (CHEKIT) ELISA (Bommeli 
Diagnostics/Intervet) and Ceditest ® FMDV-NS (Cedi Diagnostics B.V.) a 3ABC C-ELISA as well 
as the PANAFTOSA I-ELISA. The studies investigated the sensitivity (proportion of true 
positives) and the specificity (proportion of true negatives) identified by each of the tests. The 
results indicated that sensitivity and specificity of the C-ELISA and PANAFTOSA I-ELISA were 
high, whereas the CHEKIT ELISA had very low sensitivity but a high specificity (Bronsvoort et 
al., 2006). The CHEKIT ELISA showed similar results as before but the C-ELISA had a high 
sensitivity but a low specificity when compared to the VNT used as the ‘gold standard’ for 
serological testing (Bronsvoort et al., 2004). The authors state that the use of the VNT as a 
‘gold standard’ is questionable due to the different antibody responses in cattle giving 
unreliable results. Therefore, there might be justification in only comparing NSP tests to each 
other, without assuming the status of the animals using the VNT. The indirect- and 
competition-ELISAs have been shown to be highly effective but due to high variability in 
specificity, false positives might overwhelm sero-surveillance of large populations and the use 
of EITB in combination might be necessary. 
1.6 COMPETITIVE-ELISA  
Competitive-ELISAs have been shown to be highly sensitive and specific in the detection of 
binding antibodies towards NSPs of FMDV (Bronsvoort et al., 2006). This method of diagnosis 
has an advantage over the commonly used I-ELISA for FMDV detection. With the virus being 
able to infect multiple species, diagnosis using an I-ELISA would require a range of host 
specific secondary-conjugated antibodies for detection. This makes screening livestock an 
expensive and complex process, whereas the workings of a C-ELISA would only require one 
detection antibody irrespective of the origin of the serum. In an I-ELISA, NSPs are used as the 
capture antigens in these tests and it is the detection of bound antibodies from animal serum 
to these antigens that would confirm infection. In a C-ELISA the same NSPs are coated but 
when the suspected animal serum is added, a known antibody is added which competes for 
the binding of the antigen (hence termed competitive-ELISA) (Figure 1.4). Therefore, to 
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determine infection, the detection of the known antibody through the use of a specific 
secondary conjugate can be achieved. The detection signal would therefore be inversely 
proportional to the infection status.  
1.6.1 ANTIBODY PRODUCTION 
Antibodies are used in many applications including research, therapeutics and diagnostics. 
Polyclonal antibodies have been useful for the detection of multiple antigens, widely used in 
research and diagnostics, but the sera contain a diverse number of different antibodies which 
have unknown specificities. Therefore, monoclonal antibodies (mAbs) are greatly sought after 
due to their specific binding capabilities. The breakthrough that was hybridoma technology 
gave rise to the continuous production of specific mAbs (Köhler and Milstein, 1975).  
The production of a mAb initially starts by immunising an animal with the desired target 
protein/antigen, then extracting the immune cell from the spleen and fusing these cells to 
myeloma cells to create immortalised hybridoma cell lines that continuously produce mAb 
(Ward et al., 1999). Antibody phage display and other technologies have improved the 
screening and generation of monospecific binders but effective production systems are 
limiting (Schirrmann et al., 2011). Immunoglobulins (Igs) consist of heavy and light chains (HC 
and LC) that require sophisticated folding to generate the intramolecular disulphide bonds 
(SS) for stabilisation (Figure 1.3). Many commonly used host expression systems (e.g. 
bacteria) do not facilitate the mechanisms required for complex folding and therefore smaller 
antibody fragments were designed (Boss et al., 1984). These fragments consist of only the 
variable region of the Ig molecule and therefore still have the binding capacity of the full Ig 
but a reduced complexity. These variable fragments consist of the heavy and light variable (VH 
and VL) regions which can be linked together for stabilisation, to create a single chain variable 
fragment (scFv) (Figure 1.3) (Frenzel, Hust and Schirrmann, 2013). Improvements in 
recombinant DNA technology and antibody engineering have now allowed for antibody 
fragments or scFv genes to be cloned and expressed in a magnitude of systems; bacteria 
(Skerra and Plückthun, 1988), yeast (Gram and Ridder, 2001), mammalian (Ho, Nagata and 




1.6.2 COMPETITIVE-ELISA REAGENTS FOR FMDV DIAGNOSIS 
It has been mentioned previously that NSPs have successfully been shown to DIVA when used 
in ELISAs. In a C-ELISA the 3ABC polyprotein has again been shown to function well as the 
coating antigen to detect infection. In many cases, the 3ABC antigen is expressed within E. 
coli and once purified, used to coat the wells of the ELISA plate. The competing antibody 
however, has been used from different sources. The work done by Clavijo et al. (2004) used 
purified E. coli-expressed 3ABC antigen to infect guinea pigs and the serum (polyclonal) was 
successfully used as the competing antibody (Clavijo et al., 2004). Similarly, work done by 
Figure 1.3. Diagram showing full immunoglobulin (Ig) and scFv.  
The full Ig molecule consisting of the heavy and light chains (HC and LC), the heavy and light variable (VH and VL) regions and 




Sharma et al. (2012), expressed the 3ABC polyprotein in E. coli and once purified, monoclonal 
antibodies were developed by hybridoma cell lines (Sharma et al., 2012). These studies were 
successful in distinguishing infected from vaccinated animal serum but the use of animals and 
hybridoma culture is a lengthy, complex and expensive approach for continual antibody 
production. In order to circumvent this problem a group decided to use antibody phage 
display technology in order to generate a phage display library of recombinant scFvs which 
could be used as the competing binding antibody in a C-ELISA to diagnose FMDV. Foord et al. 
(2007) used recombinant E. coli-expressed and purified 3ABC polyprotein (NSP) to immunise 
chickens. A chicken phage display library was made and biopanning used to isolate the 3ABC-
specific phage antibody clones, which when sequenced revealed three distinctive genetic 
sequences. 
The three specific scFv genes were expressed in an E. coli system, and when tested showed 
binding capabilities to the 3ABC polyprotein, specifically to epitopes on the 3B region. The 
three-chicken recombinant antibody-foot-and-mouth (CRAb-FM) 26, -27 and -29 clones were 
Figure 1.4. Diagram of a competitive-ELISA showing how differentiation of infected and healthy or vaccinated animals 
would be performed with a scFv as the competing agent.  
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evaluated in a C-ELISA. The CRAb-FM27 clone was best for differentiating sera from pigs, 
cattle and sheep that were from naïve, FMDV-infected and FMDV-vaccinated samples (Foord 
et al., 2007). This is the first serological diagnostic assay which successfully derived both 
antigen and detecting scFv from a bacterial expression system for FMDV diagnosis. This safe 
and economic production of diagnostic reagents without the need for live virus and the costly 
use of continuous cell culture maintenance is most desirable. 
1.7 THE SOUTH AFRICAN DILEMMA 
South Africa (SA) is considered a FMDV-free without vaccination country but with the Kruger 
National Park (KNP) being recognised as the only infected area within the country. The 
epidemiology of the disease has shown that all three SAT serotypes of the virus are 
maintained within the African buffalo (Condy et al., 1985; Di Nardo et al., 2015) and that more 
than 70 other species of wildlife can be infected (Grubman and Baxt, 2004). The prevalence 
of the virus within these animals has created a reservoir for the virus, making the KNP a 
lingering threat to South Africa.  Recommendations by the OIE were to isolate the KNP from 
the rest of the country using game-proof fencing and to set up a buffer zone adjacent to the 
park and a surveillance zone just outside of that, for livestock to be continuously monitored 
(Figure 1.5). In the buffer zone, animals are vaccinated twice a year with a trivalent SAT 1, 2 
and 3 vaccine. There is a seven-day inspection of livestock and strict movement of animals 
and animal products into the surveillance and free zones for outbreak mitigation. There are 
14-day inspections of livestock within the surveillance zone, along with ongoing serological 
testing of serum of animals translocating into the free zone. There is also continuous 
monitoring taking place within the KNP and other private game reserves holding wildlife, 
specifically within the African buffalo (Syncerus caffer) population (Brückner et al., 2002).  
With vaccinations taking place in and around the park, distinguishing infected from vaccinated 
animals is of great importance. Complications have arisen in the past, during emergency 
outbreaks, where animals had come into contact with infected wildlife and DIVA recognition 
of livestock sera was required. The large number of livestock and wildlife sera obtained from 
this continuous monitoring requires the need for level 3 bio-containment facilities. South 
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Africa’s Exotic Disease Division at the Onderstepoort Veterinary Institute (EDD-OVI) in 
Pretoria was founded to handle highly contagious diseases such as FMDV and African swine 
fever. This facility routinely manages between 20-30 thousand serological tests per year, 
which can increase to around 75 000 during an outbreak (Brückner et al., 2002).  
Outbreaks are known to put tremendous strain on a nation’s economy from the direct and 
indirect impact the virus has on animals. In September 2000 to February 2001 SA experienced 
outbreaks in Mpumalanga, KwaZulu-Natal and Mhala. The total operational costs to contain 
the problem including having over 900 personnel to maintain roadblocks, set up animal 
quarantine camps, dispose of culled animals, control bio-security cordons and perform 
continuous diagnosis, was estimated at ZAR90 million (Brückner et al., 2002). The monitoring 
of animals around the KNP may be challenging and expensive but controlling the spread and 
returning a region to a FMDV-free status is even more so and adds to the stress put on the 
economy. This illustrates the importance of having a fast, accurate diagnostic protocol as well 
as a more cost-effective one to limit the enormous costs of containment.  
Figure 1.5. Indicating the areas of South Africa where FMDV is controlled.  
 
The control zones located next to the Kruger National park and neighbouring countries and the white zone indicating 
the FMDV-free zone. Figure taken and adapted from Brückner et al. (2002). 
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1.8 PLANT EXPRESSION AS A SOLUTION 
The advancement over the last few decades in recombinant DNA technology has given rise to 
a multitude of different protein expression systems. Recombinant proteins used for research, 
diagnostics and therapeutics have been expressed in both prokaryotic and eukaryotic cell 
systems, each of which systems having different advantages. The shared objective in the 
ongoing research is to identify a single system that has the collective advantages of these. The 
model expression system would offer high levels of functionally active proteins which are 
safe, production of which would be scalable, and could be produced at a reduced cost. The 
expression of recombinant DNA in mammalian cells has produced biologically active 
molecules but, scalability of this system is costly as cell culture maintenance is expensive. This 
system is also susceptible to human or other mammalian pathogen contamination which can 
present a considerable threat if used as a therapeutic. Microorganisms have been modified 
to accommodate high levels of production, however, these products are also limited due to 
the considerable difference between the natural protein and the bacterially-expressed ones. 
An example of this is the lack of post-translational modifications often required for correct 
conformation and folding through disulphide bridges and glycosylation, which is seen in 
mammalian but not bacterial systems (Egelkrout, Rajan and Howard, 2012). 
The use of plants as a recombinant protein expression system in recent years has shown 
potential for covering many of these advantages, and has been proposed as an effective 
alternative expression system (Hefferon, 2014). Firstly, plants are a more economically viable 
method of production in comparison to mammalian cell culture, which has been shown in 
antibody production (Nandi et al., 2016). Secondly there is no risk of containing retroviruses 
or other pathogens which can occur in cell cultures. Thirdly, plants contain a secretory 
pathway and endomembrane system similar to that of mammalian cells, which allows for 
post-translational modification of recombinant proteins which is not observed in bacterial 
production of complex proteins (Chen et al., 2013).  
The transformation of plants with foreign DNA can be done by a physical or biological means. 
Physically a particle gun, electroporation or PEG-mediated transformation can be used to 
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transform plant cells with recombinant DNA for transgenic or transient expression (Rao et al., 
2009). The advantage with physical transformation is that it is simple but, complications can 
arise when the physical toll on the host tissue causes cell damage during transformation, 
reducing successful integration  (Egelkrout, Rajan and Howard, 2012). The biological means 
of transformation involves the natural ability of Agrobacterium to incorporate its transferred-
DNA (T-DNA), located on the tumour inducing (Ti) plasmid, into the plant cell. The left and 
right borders (LB and RB) located on either side of the T-DNA are used to harbour recombinant 
DNA which would then be transferred and transcribed within the plant cell  (Tzfira and 
Citovsky, 2006). This can facilitate episomal transient expression, using either plasmid or 
replicating plant virus-derived vectors, or stable transformation using non-viral vectors 
(Egelkrout, Rajan and Howard, 2012).  
Transgenic expression of recombinant proteins is often highly successful, and once the gene 
has been integrated into the plant genome, it is stable over many generations (Li et al., 2006). 
However, this approach is often time consuming as several months are required for 
transformation, which limits high throughput investigation of highly expressed recombinant 
proteins. Once generated, the stable transgenic lines are considered genetically modified 
organisms (GMO) and precautions would need to be taken to prevent exposure to the 
environment, which again adds to the cost of production (Rybicki, 2009).  
The advantages of using transient expression is that a larger variety of proteins can be 
screened for possible expression in a plant system in a shorter period of time, hence 
improving high throughput testing. The yields have been shown to be competitive with 
transgenic and other expression systems (Gleba, Klimyuk and Marillonnet, 2007). Moreover, 
containment is not an issue as the genes are somatically expressed and are not heritable. 
Simple transient expression is achieved using modified Agrobacterium-derived plasmid 
vectors, which do not replicate in plant cells. The virus-derived vectors which do replicate 
consist of two types: these are first generation and second-generation vectors. The first 
generation of viral vectors (gene substitution and gene insertion vectors) involved the use of 
fully functional RNA plant viruses, which contained the coding sequence of the gene of 
interest. The gene of interest is usually expressed from a strong viral promoter like the coat 
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protein promoter. The limitations of the full-virus approach are that large inserts of >1Kb are 
not usually expressed and only short peptides could be expressed fused to the viral coat 
protein. The infection process is usually slow and asynchronous leading to not all parts of the 
plant being infected, and the vectors are generally unstable which leads to issues of low yields 
of protein. These limitations prompted the development of the second generation of vectors 
(deconstructed and modular viral vectors, both RNA and DNA), which involve the use of 
deconstructed virus vectors containing only the elements necessary for expression. These 
second-generation viral vectors combined the best features of viruses for their speed and 
high level of expression and the efficiency of transformation using Agrobacterium. The 
deconstructed RNA viral vectors gave rise to a new expression strategy in plants, called 
magnifection (Gleba, Klimyuk and Marillonnet, 2007).  
Magnifection in essence uses deconstructed viral vectors that have been integrated between 
the LB and RB into a single modified Ti plasmids of Agrobacterium for the transformation and 
recombinant protein expression in plant tissue (Gelvin, 2003; Gleba, Klimyuk and Marillonnet, 
2005, 2007; Lico, Chen and Santi, 2008).  
The modular vector system utilises binary vectors which contain the essential components of 
the viral vectors, along with the gene of interest between the LB and RB on a separate T-DNA 
plasmid. The Ti plasmid, would have the virulence genes acting in trans to transfer the T-DNA. 
This modified Ti plasmid is referred to as the helper plasmid (Lee and Gelvin, 2007; Shah, 
Almaghrabi and Bohlmann, 2013). The two systems of second generation vectors uses the 
process of Agrobacterium-mediated transfer to introduce the bacteria into the plant by 
vacuum or syringe infiltration (Chen et al., 2013). This process addresses the limitations of the 
earlier expression based technologies in plants by having: increased levels of protein 
expression and high yields, faster and cheaper research and development, and reduced costs 





1.9 AIMS AND OBJECTIVES 
The Foot-and-mouth disease virus has been shown to be a lingering threat to South Africa as 
the wildlife in the KNP and other wildlife reserves act as a viral reservoir. FMD is one of the 
most devastating diseases for any country’s economy, where billions of dollars have been 
spent to mitigate outbreaks and eradicate it. The nations which have successfully done so, 
have gained the FMDV-free status from the OIE, which allows them to maintain animal and 
animal product trading with other FMDV-free countries. Once declared as FMDV-free, 
maintaining this status requires strict monitoring of livestock through various diagnostic 
methods prescribed by the OIE. These are used to prevent or detect possible outbreaks as 
soon as possible and to reduce the direct and indirect impact of the virus. This monitoring of 
animals is generally done during their import and export but SA also has the viral reservoir to 
consider. This additional burden requires continuous inspection of animals around 
susceptible areas, which adds to the huge cost associated with outbreak mitigation. The cost 
of diagnosis varies depending on the inquiry and method required to answer it. The 
Agricultural Research Council (ARC) at the Onderstepoort Veterinary Institute supply a price 
list for each test. The range of these costs per animal are; ZAR229 (NSP-ELISA test to DIVA), 
ZAR367 (VNT), ZAR555 (virus isolation), ZAR1963 (RT-PCR) and over ZAR2000 for sequencing 
(ARC, 2017).  
Vaccines are used around the buffer and surveillance zones of the KNP and therefore regular 
inspection requires rapid diagnoses that involves distinguishing infected from vaccinated 
animals. The NSP-ELISA is used for this as it is the quickest of the tests (4 days compared to 5-
8 days for VNT or virus isolation), can distinguish infected from vaccinated animals and is the 
cheapest (ARC, 2017). 
The focus of this project, therefore, was to determine if diagnostic reagents for DIVA ELISA 
tests could be made in a plant expression system, and to test whether they were functional, 
and whether they could be made less costly. The reagents investigated were the highly 
immunogenic 3ABC NSP of the virus and a scFv (CRAb-FM27) found previously in another 
laboratory to recognise the 3ABC polyprotein. Expression and functionality of truncated 
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versions of the 3ABC polyprotein were also tested (3AB1, 3AB and 3B). The expression and 
functionality of a plant-produced CRAb-FM27 scFv, previously shown to be functional in a C-
ELISA to DIVA sera (section 1.6.2) was also investigated.  
The objectives of the project were:  
• To transiently express these FMDV NSPs in a plant system and purify them using 
immobilized metal-ion affinity chromatography (IMAC). The plant expression vectors 
used are the autonomously replicating geminivirus-derived pRIC3.0 (Regnard et al., 
2010) and the non-replicating pTRAKc. The same NSPs were to be expressed and 
purified in an E. coli system to serve as positive controls and a point of reference for 
comparison to plant expression.   
• To transiently express the CRAb-FM27 scFv in a plant system using the pTRAKc vector 
and to purify it using IMAC. E. coli-expression of the scFv was to be done again to serve 
as a positive control during plant expression and to compare its functionality to the 
plant made one.  
• To test these two reagents for functionality using an indirect-ELISA and again in 
tandem in a competitive–ELISA to determine if they are able to differentiate between 










EXPRESSION AND PURIFICATION OF FMDV 3ABC VARIANT 
ANTIGENS IN E. COLI AND N. BENTHAMIANA  
2.1 INTRODUCTION 
The types of diagnostic reagents required for use in FMDV antibody detection differ 
depending on whether the FMDV serotype is to be identified or if the animal’s status needs 
to be distinguished from infected or vaccinated. In an FMDV-free country that does not 
require vaccination of animals, animal serum would only need to be tested for the presence 
of antibodies as a result of infection and therefore structural proteins (SPs) could be used in 
a serotype-specific ELISA test to determine this. Countries that have FMDV-free with 
vaccination status, would need to differentiate between the animals that have been 
vaccinated and those that are infected. Serological tests using ELISAs with non-structural 
proteins (NSPs) of the virus are employed to do so, as only binding antibodies from an infected 
animal would be detected.  
Buffalo and other animals in the Kruger National Park in South Africa act as a reservoir for the 
virus, and vaccination of cattle is therefore used in the buffer zone surrounding the park to 
prevent spread. Accordingly, it is of great importance that the animals translocating from 
controlled zones into FMDV-free areas of the country are distinguishable from infected ones. 
This becomes an expensive process, and with a range of serological, immunological and 
nucleic acid tests being used (e.g. VNT, CFT and RT-PCR), the NSP-ELISA is the quickest and 
cheapest option.  
A variety of non-structural proteins exists as part of the virus’s replicating machinery and 
much research has been done to determine the most immunogenic ones. Research has shown 
that the 3ABC polypeptide has worked well in an ELISA as a NSP diagnostic reagent for the 
detection of anti-FMDV antibodies. Variations or truncated regions of the full 3ABC 
polypeptide (3AB1, 3AB and 3B123) have also been shown to be as effective in an ELISA to 
26 
 
distinguish infected from vaccinated animal serum. The polyprotein consists of three main 
parts: region 3A helps anchor the viral transcripts to the ER; the 3B region consists of three 
non-identical segments B1, B2 and B3 each of which encode a viral genome-linked protein 
involved in the initiation of RNA synthesis and encapsulation of viral RNA; and, the 3C region 
is a protease (3Cpro) that is involved in cleavage of the 3ABC polyprotein into its individual 
components. 
The important characteristic of an antigen used as a diagnostic reagent is its ability to 
distinguish infected from vaccinated animals (DIVA). The main focus of this project was to 
explore the expression of these known NSPs in plants, which could lead to an increased level 
of protein containing the necessary post-translational modifications and which could 
potentially be used as an alternative expression platform for more cost-effective diagnostic 
reagent production. The testing of FMDV 3ABC expression and several variants thereof in the 
plant Nicotiana benthamiana was accordingly carried out in five studies.  The first two studies 
included using the whole polyprotein of two different serotypes: these were serotype O 
(3ABC-O) and serotype A (3ABC-A).  These have previously been shown to be successfully 
expressed in an E. coli system and were used as reagents in ELISAs for FMDV detection. The 
third study used a truncated version of the 3ABC-O protein which lacks the 3Cpro region, 
yielding the 3AB variant (3AB-O). The fourth involved the removal of the 3A and 3Cpro regions 
from 3ABC serotype O, giving rise to the 3B123 region (3B-O). The final variant was the 3AB1 
protein, which is used at the National Agricultural Technology Institute (INTA) in Argentina 
(3AB1-Arg). Expanding the range of antigen types by having multiple variants of 3ABC was 
thought to broaden the chances of achieving successful expression in plants. 
Genes encoding the protein variants described above were cloned into two plant expression 
vectors, pRIC3.0-HT and pTRAKc in order to compare expression levels of recombinant 
proteins.  Transient expression of these proteins in N. benthamiana was done using two 
different binary vectors. The pRIC3.0-HT vector was selected as it functions to increase 
expression by autonomous replication. The expression for each protein using pRIC3.0-HT 
vector was compared to the pTRAKc vector, which is non-replicating.  
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In addition, the same genes were cloned into the E. coli expression vector pProEX-HTb in order 
to produce recombinant protein of the cognate variants for positive controls as well as to be 
compared to the functionality of the plant produced antigens during testing of the proteins 
against animal serum (described in Chapter 4). 
2.2 MATERIALS AND METHODS 
2.2.1 PLASMID AMPLIFICATION AND ISOLATION.  
The plant and E. coli expression vectors were maintained in E. cloni® DH5-α competent cells 
(Lucigen, USA). These vectors included the pProEX-HTb (Thermo Fisher Scientific) E. coli 
expression vector and the pRIC3.0-HT (Biopharming Research Unit (BRU) in the department 
of Molecular and Cell Biology (MCB) at the University of Cape Town) and pTRAKc-ERH 
(supplied by Rainer Fischer, Fraunhofer Institute, Aachen) plant expression vectors. Cultures 
were streaked out on Luria-Bertani (LB) (1.0% Tryptone, 0.5% Yeast Extract, 1.0% NaCl, 1.5% 
Bacterial Agar) plates containing the appropriate antibiotics for selection (Table 2.1) and 
incubated overnight at 37°C. Colonies for each clone were inoculated in 10ml LB broth with 
the relevant antibiotics and incubated overnight at 37°C. Plasmid DNA was extracted from 
overnight cultures using the QIAprep Spin Miniprep kit (QIAGEN, USA) and DNA 
concentrations were measured using a UV-VIS NanoDrop spectrophotometer (NanoDrop 
technologies, USA) at a wavelength of 260nm. 
 
Table 2.1. Antibiotics used for bacterial selectivity.  
Vector Bacterial strain Selective antibiotic 














2.2.2 CONSTRUCT DESIGN AND SYNTHESIS.  
Three variants of the antigen gene were synthesised: the first was the full 3ABC polypeptide 
from FMDV serotype O (3ABC-O) (GenBank, Accession number AY614501) which was wild 
type and had no modifications. The second was the full polypeptide gene from serotype A 
(GenBank, Accession number AFE84732), which contained mutations (mu3ABC-A). The third 
was only the 3B region of the polypeptide from serotype O (3B-O) and the fourth was the 
3AB1 region of the polypeptide from serotype A (3AB1-Arg, sequence obtained from INTA). 
Synthesis of the antigen genes was done by GenScript (China): these were codon optimised 
for Nicotiana benthamiana and cloned in pUC57. All genes contained a protein disulphide 
isomerase (PDI) signal sequence (GenBank, Accession number Z11499) fused to the 5’ 
terminus. A histidine tag (6Xhis tag), was fused to the 5’end of mu3ABC-A, 3B-O and 3AB1-
Arg genes.  
2.2.3 SITE DIRECTED MUTAGENESIS.  
It is hypothesised that the 3Cpro region of the polyprotein could possibly be responsible for a 
reduction of recombinant 3ABC expression due to it causing proteolysis of host cell proteins. 
Therefore site-directed mutagenesis (SDM) was employed to disrupt the active site of the 
3Cpro region. The 3ABC-O gene was used as the template for SDM of the 3Cpro region of the 
polypeptide as first described by Ho et al. (1989) and resulted in the mu3ABC-O variant. Two 
mutations (Cys 142 Ser and Cys 163 Gly) were added by substitution of single base pairs using 
sets of primers (Table 2.2) and PCR. This was done using flanking primers (For-A and Rev-D) 
to bind either end of the target sequence along with internal primers (For- C1+TaqI and Rev-
B1+TaqI) containing mismatched bases to bind the region where the mutation occurred. The 
first round of PCR created the AB and CD fragments which were run on an agarose gel and 
purified. These fragments were mixed together along with the flanking primers for the second 
round of PCR. The B and C region of the fragments were complementary to each other, 
containing the changed sequence, and therefore hybridised and in turn created the new 
internal primers resulting in the final A to D sequence containing the first Cys142Ser mutation. 
The complete mutated fragment was run on an agarose gel, purified and ligated into the 
pJET1.2/blunt cloning vector (Thermo Scientific, CloneJET PCR Cloning Kit) as per the 
manufacturer’s instructions. Mini-prepped plasmids of the first mutation were then subjected 
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to the same procedure for introduction of the second mutation using the same flanking 
primers but different internal ones (For-C2+MnlI and Rev-B2+MnlI). All PCRs were performed 
using a high fidelity DNA polymerase (Accuzyme™, Bioline) as per the manufacturer’s 
instructions, to reduce misreading and for blunt end formation of products. 
Confirmation of the added mutations was done using the RE digest of the final sequence. The 
mutations were created such that the sequence change at the nucleotide level created a 
synonymous mutation to include restriction enzyme sites. The Cys142Ser mutation created a 
TaqI restriction site and the Cys163Gly mutation created a MnI restriction site. Digestion of 
the mutated gene with the respective enzymes was performed and run on a 2.5% agarose 
gel. The banding pattern observed would determine if the mutation was made or not.  
Table 2.2. Primers and conditions used for site-directed mutagenesis. Red nucleotides indicating base change for 
substitution mutations and underlined regions indicating RE sites. 
Round Primers Conditions 
Mutation 1 
(Cys142ser) 
TaqI RE site 
 
For-A 5’- GACCATGGCGAATGT-3’ 
Rev-B1+TaqI 5’- CCATCCATCGATACAACA-3’ 
Denatured at 95°C for 30 sec 
Annealing at 42°C for 30 sec 
Extension at 72°C for 1 min 30 sec 
Final Extension at 72°C for 2 min 
30 cycles 
For- C1+TaqI 5’- TGTTGTATCGATGGATGG-3’ 
Rev-D 5’- ATCTCGAGTCATTCGTGGTG-3’ 
Mutation 2 
(Cys163Gly) 
MnlI RE site 
 
 
For-A 5’- GACCATGGCGAATGT-3’  
Rev-B2+MnlI 5’-GCTCCACCTCCGTAACCAG-3’ 
Denatured at 95°C for 30 sec 
Annealing at 45°C for 30 sec 
Extension at 72°C for 1 min 30 sec 
Final Extension at 72°C for 2 min 
30 cycles 
For-C2+MnlI 5’- CTGGTTACGGAGGTGGAGC-3’ 
Rev-D 5’- ATCTCGAGTCATTCGTGGTG-3’ 
 
2.2.4 TRUNCATION OF 3ABC-O.  
The pUC57-3ABC-O plasmid was subjected to PCR in order to truncate and remove the 3Cpro 
region of the polypeptide gene. This was done using a high fidelity DNA polymerase along 
with specific primers and cycling conditions (Table 2.3). Amplification of the 3AB region would 
result in the loss of the 3C region and the 3AB-O gene was ligated into the pJET1.2/blunt 
cloning vector as per manufacturer’s instructions. The variations of the 3ABC gene, its 




Table 2.3. Primers and conditions used for 3ABC-O truncation. 





Denatured at 95°C for 30 sec. 
Annealing at 50°C for 30 sec. 
Extension at 72°C for 1 min 30 
sec. 





Figure 2.1. Schematic of the five 3ABC NSP gene variants.  
Mu3ABC-A, 3B-O and 3AB1-Arg have a 3’ 6Xhis tag, whereas the mu3ABC-O and 3AB-O genes do not. They each contain a 5’ PDI 




2.2.5 CLONING STRATEGY AND SUBCLONING.  
The cloning strategy for the 3ABC-O, mu3ABC-O and 3AB-O genes into the plant expression 
vectors was as follows: cloning of the genes into pRIC3.0-HT was done by restriction enzyme 
(RE) digest using the 5’ NcoI and 3’ XhoI sites. These sites allowed for the retention of the 
6Xhis tag within the vector at the 5’ end. Cloning of these same genes into the pTRAKc-ERH 
vector used the same restriction enzymes. This resulted in the retention of the 5’ lactase-
phlorizin hydrolase (LPH) signal sequence (Maclean et al. 2007), which is used as an ER 
targeting signal, but the removal of the 6Xhis tag and SEKDEL signal (ER retention signal) 
within the vector.  
The cloning strategy for the mu3ABC-A, 3B-O and 3AB1-Arg genes into the two plant 
expression vectors was as follows: The pRIC3.0-HT vector was digested at the AflIII and XhoI 
sites and the genes digested using the NcoI and XhoI sites. Ligation of the gene into the vector 
abolished the NcoI site and removed the native 6Xhis tag within the vector. The same genes 
were cloned into the pTRAKc-ERH expression vector using EcoRI and XhoI. This resulted in the 
removal of the LPH signal, 6Xhis tag and SEKDEL signal from the vector. 
The cloning strategy for 3ABC-O, mu3ABC-O, 3AB-O, mu3ABC-A, 3B-O and 3AB1-Arg genes 
into the E. coli expression vector (pProEX-HTb) was done using the NcoI and XhoI RE sites. The 
use of these sites resulted in the retention of the 5’ 6Xhis tag in the expression vector. The 
3ABC-O, mu3ABC-O and 3AB-O genes do not contain a 6Xhis tag and therefore would only 
contain one 5’ 6Xhis tag from the vector. The mu3ABC-A, 3B-O and 3AB1-Arg genes already 
had a 6Xhis tag fused to the 3’ terminus and therefore once cloned into pProEX-HTb would 
contain both a 5’and 3’his tag. See Table 2.4 for final constructs.     
All plasmids (100ng) were digested using appropriate restriction enzymes (Thermo Fisher 
Scientific) incubating for 1 hour at 37°C and fragments resolved by electrophoresis at 120 
Volts (V) for 1 hour on a 1% agarose gel (0.5 µg/ml)0.04 µl/ml ethidium bromide). 
O’GeneRuler 1kb DNA ladder (Fermentas, Canada) was used to determine the size of the DNA 
32 
 
fragments. A QIAquick gel extraction kit (Qiagen, USA) was used to purify the inserts and the 
expression vector fragments from the gel, as per manufacturer’s instructions. A ligation 
reaction of 1:3 (vector: insert) molar ratio was used and T4 ligase (Fermentas, Canada) was 
added and incubated overnight at 4°C for ligation. Transformation of recombinant plasmids 
into E. cloni® DH5α competent cells was performed as per manufacturer’s instructions. 
Table 2.4. Showing final cloned antigen genes into E. coli and plant expression vectors. 
 
2.2.6 RECOMBINANT PLASMID CONFIRMATION.  
In order to confirm successful transformation of recombinant expression vectors into either 
E. coli or A. tumefaciens, colonies were screened using polymerase chain reaction (PCR). All 
PCR reactions were done using the Bio-Rad MyCycler (Bio-Rad Laboratories, USA) and 
KAPATaq ready mix (KAPABiosystems, USA, KK1024). PCR reactions were performed per the 
manufacturer’s instructions in 20µl reactions. PCR products were resolved on an agarose gel, 
along with a 1kb DNA ladder as described in section 2.2.5. Primers and cycling conditions for 
each set of reactions are shown in Table 2.5. Primers were synthesised by the MCB 
Oligonucleotide Synthesis Service, UCT. 
Confirmation of recombinant expression vectors was also achieved using restriction enzyme 
analysis. Each recombinant plasmid was mini-prepped and digested using the same REs as 
used in the cloning steps in section 2.2.5. The fragments were resolved on an agarose gel to 
observe the banding pattern. Confirmation of recombinant vectors was also achieved via 
sequencing (Macrogen). Theoretical subcloning of the various genes into the expression 
vectors was initially done using CLC Genomics Workbench (Qiagen).  
Five 3ABC NSP 
gene variants 
E. coli expression vector Plant expression vectors 
pProEX-HTb pRIC3.0-HT pTRAKc 
3ABC-O pProEX-HTb-3ABC-O pRIC3.0-HT-3ABC-O pTRAKc-3ABC-O 
Mu3ABC-O pProEX-HTb-Mu3ABC-O pRIC3.0-HT-Mu3ABC-O pTRAKc-Mu3ABC-O 
Mu3ABC-A pProEX-HTb-Mu3ABC-A pRIC3.0-HT-Mu3ABC-A pTRAKc-Mu3ABC-A 
3AB-O pProEX-HTb-3AB-O pRIC3.0-HT-3AB-O pTRAKc-3AB-O 
3AB1-Arg pProEX-HTb-3AB1-Arg pRIC3.0-HT-3AB1-Arg pTRAKc-3AB1-Arg 
3B-O pProEX-HTb-3B-O pRIC3.0-HT-3B-O pTRAKc-3B-O 
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Table 2.5. Vector specific primers and conditions used for colony PCR. 
 
2.2.7 E. COLI EXPRESSION OF RECOMBINANT PROTEIN.  
The recombinant pProEX-HTb antigen constructs and empty pProEX-HTb (negative control) 
were maintained in E. coli glycerol stocks (25% glycerol) and inoculated initially in 10ml LB 
broth with appropriate antibiotics (Table 2.1). These were incubated at 37oC with shaking 
overnight (16-18 hours). The starter cultures were used to inoculate a 50ml LB broth with 
appropriate antibiotics and again incubated overnight at 37°C. The pProEX™ HT Prokayotic 
Expression System (Thermo Fisher Scientific) protocol was followed as per manufacturer’s 
instructions. The culture was induced using isopropyl β-D-1-thiogalactopyranoside (IPTG), at 
a final concentration of 0.6mM, when the optical density (OD600) reached 0.6-0.1 (exponential 
growth phase). The culture was again incubated at 37oC. As a small-scale time trial, 1ml 
samples were taken every hour for 3 hours after induction and analysed for optimisation 
purposes. Large scale expression was done using the optimised time of harvest determined 
in the small-scale trial. The cultures were centrifuged (10 000xg) for 10 minutes after the 
incubation period and the pelleted cells’ wet weight was determined. The cell pellets were 
kept for protein extraction.  
 
 
Vector Primers Conditions 
pProEX-HTb Forward 5’-CGTACTACCATCACCATCAC-3’ 
Revers 5’-TGATTTAATCTGTATCAGGCTG-3’ 
Initial denaturing 95°C for 5 min 
Denatured at 95°C for 30 sec 
Annealing at 55°C for 30 sec 
Extension at 72°C for 1 min 30 
sec 
Final Extension at 72°C for 2 min 
30 cycles 
pRIC3.0-HT Forward 5’-ATCCTTCGCAAGACCCTTCCTCT-3’ 
Reverse 5’-AGAGAGAGATAGATTTGTAGAGA-3’ 
Initial denaturing 95°C for 5 min 
Denatured at 95°C for 30 sec 
Annealing at 54°C for 30 sec 
Extension at 72°C for 1 min 30 
sec 





2.2.8 RECOMBINANT E. COLI PROTEIN EXTRACTION.  
The extraction of recombinant protein from the E. coli cell pellet from section 2.2.7 was 
achieved using the BugBuster™ protein extraction reagent (Novagen). The empty vector 
negative control cells were treated in the same way during extraction. The protocol was 
followed for soluble protein extraction, as per the manufacturer’s instructions. The pellet, 
collected after isolation of the soluble fraction, was kept and resuspended in 2ml extraction 
buffer (1X phosphate-buffered saline (PBS), 8M urea, pH8) (same buffer as the equilibration 
buffer for batch binding). This was kept shaking at room temperature (22-24oC) for 1 hour to 
allow for disruption of inclusion bodies and solubilisation of proteins. Centrifugation at 
10 000xg for 20 minutes was done to isolate the supernatant, which was kept at -20oC for 
later analysis.    
2.2.9 AGROBACTERIUM TUMEFACIENS TRANSFORMATION.  
A. tumefaciens strain GV3101::pMP90RK was obtained from culture collection of the BRU. 
The cells were made electrocompetent using the method described by Wen-Jun and Forde 
(1989). A 100µl volume of thawed electrocompetent cells were added to a chilled 0.1cm 
electroporation cuvette (Bio-Rad, USA) and 400ng of recombinant plasmid DNA was added 
and mixed. Cells were electroporated using a GenePulser (Bio-Rad, USA) set at 1.8kV, 25µF 
and 200Ω. Transformed cells were then combined with 900µl LB broth and incubated for 2 h 
at 27°C. Cells were plated onto LB plates with appropriate antibiotics (Table 2.1) and 
incubated for 2 days at 27°C. Colony PCR was used to screen transformed colonies as 
described before in section 2.2.6. Selected colonies were inoculated into 10ml LB broth with 
the respective antibiotics and incubated overnight at 27°C. 
2.2.10 A. TUMEFACIENS-MEDIATED TRANSIENT EXPRESSION.  
Starter cultures of A. tumefaciens containing recombinant pRIC3.0-HT or pTRAKc constructs 
(Table 2.4) were grown in LB broth with the appropriate antibiotics (Table 2.1) at 27oC 
overnight (Maclean et al., 2007). The empty pRIC3.0-HT and pTRAKc vectors in A. tumefaciens 
cells were grown in the same way to be used as negative controls. 
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Starter cultures were used to inoculate LB Broth base (LBB) (Tryptone 2.5g/L, Yeast extract 
12.5g/L, NaCl 5g/L, 10 mM 2-morpholinoethanesulfonic acid [MES], 20 μM acetosyringone in 
water, pH 5.6) with the appropriate antibiotics (Table 2.1) and incubated at 27oC overnight 
with agitation.  
Cultures were diluted to the required optical density (OD600) in a resuspension solution (10 
mM magnesium chloride (MgCl2), 10 mM MES, and 200 μM acetosyringone in water, pH 5.6). 
Each of the constructs were infiltrated into six-week-old N. benthamiana plants as a small-
scale time trial at varying OD600 of 0.5 and 1.0. Each construct consisting of a different OD600 
suspension was injected into the abaxial side of the leaves of one plant, using a blunt-end 
syringe (Maclean et al., 2007).  
Larger scale vacuum infiltration of the plants was achieved by submerging the leaves from 12 
plants into the bacterial suspension and applying a negative pressure (-100KPa) under 
vacuum. The plants were again left to grow under constant conditions, 16 hours of light and 
8 hours of dark, at 24°C.  
2.2.11 RECOMBINANT PLANT PROTEIN EXTRACTION.  
The small-scale time trial of each of the expressed constructs involved harvesting equal-size 
disks (using the lid of an Eppendorf vial as a cutter) from leaves. The leaf disks were sampled 
at 1, 3 and 5 days post infiltration (dpi), and two optical densities (OD600 0.5 and 1.0) were 
investigated.  A soluble (1XPBS, pH7.4) and insoluble (1XPBS, 8M urea, pH8) extraction buffer 
was investigated and used to extract protein separately on each sample. To each, 150µl of 
extraction buffer was added and the clippings homogenised within 1.5ml Eppendorf tubes 
using micro-pestles. The samples were then centrifuged at 6000xg for 8 minutes and the 
supernatant from each collected and stored at -20oC.  
The optimal conditions for large scale expression were determined by the small-scale time 
trial, which determined at which day whole leaves should be harvested, along with the 
optimised OD600 and extraction buffer to use. Extraction buffer (1XPBS, 8M urea, pH8) was 
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added at a 1:3 weight (grams) to volume (millilitres) ratio. The leaves were then homogenised 
using a blender (Hamilton Beach Commercial, USA) and passed through Miracloth™ 
(Millipore, USA) to remove cell debris. Centrifugation at 13 000xg for 20 minutes isolated the 
supernatant which was again passed through Miracloth™ and stored at -20oC.     
2.2.12 BRADFORD ASSAY.  
Total protein concentrations from all the samples were determined using a Bradford assay 
(DC Protein Assay, Bio-Rad); the microplate assay protocol was followed as per 
manufacturer’s instructions. A standard curve using a range of bovine serum albumin (BSA, 
Thermo Scientific) at concentrations of 0.2, 0.5, 0.75, 1.0 and 1.5 mg/ml was made. Dilutions 
were made with the same extraction buffer contained in the sample. The absorbance was 
measured at 750nm on a BIO-TEK® Powerwave XS microtitre plate reader.  
2.2.13 SDS-PAGE.  
The volumes of protein samples to be tested were varied based on their total protein 
concentration in order to load equal amounts into each well. The samples (50µg total protein) 
were treated with sample application buffer (SAB) (10% SDS, 1M TrisCl pH7.5, 100mM EDTA, 
glycerol, dH2O, mercaptoethanol, bromophenol blue) and boiled for 10 minutes. Samples 
resolved at 120 V on either a 10% or 15% polyacrylamide gel by SDS-PAGE and protein sizes 
were compared against 5µl PageRuler™ prestained protein ladder (Fermentas) or Color 
Prestained protein standard, broad range (New England Biolabs).    
2.2.14 COOMASSIE BLUE STAINING.  
Visualisation of total protein on acrylamide gels was performed using Coomassie Brilliant Blue 
G250 stain (1% Coomassie blue, 48% methanol, 15% acetic acid, 36% dH2O) overnight with 
agitation. Destaining solution (30% methanol, 10% acetic acid, 60% dH2O) was added and 
agitation took place for 1 hour. Further destaining was done using 7% acetic acid for 1 -2 hours 




2.2.15 WESTERN BLOTTING.  
Once samples had been separated by SDS-PAGE, proteins were transferred to a nitrocellulose 
membrane using a Bio-Rad Trans-Blot® Semi-Dry transfer cell (Bio-Rad Laboratories, USA) set 
to 15 V and run for 1 hour. The membranes were blocked for 30 minutes using blocking buffer 
(1XPBS pH 7.4, 5% milk powder, 10% Tween 20) at room temperature with agitation. Diluted 
primary antibody (mouse anti-his (1/2000) (Bio-Rad, USA, #MCA1396)) was added to the 
membrane and left overnight at 4°C with agitation. The membrane was washed using blocking 
buffer four times and the secondary conjugate antibody (goat Anti-mouse Alkaline 
phosphatase (1/10000) (Sigma-Aldrich, USA, A3562)) was added. This was incubated at 37°C 
for 90 minutes with agitation. The membrane was then washed four times with wash buffer 
(1XPBS pH 7.4, 10% tween 20) at room temperature with agitation for 15 minutes. Once 
washed, NBT/BCIP substrate (Roche, USA) was added (2ml per blot) and the blot left in the 
dark for up to an hour for the developed bands to be visualised.    
2.2.16 BATCH BINDING PURIFICATION OF RECOMBINANT E. COLI ANTIGEN.  
Purification of the recombinant E. coli-expressed proteins was done using immobilized metal-
ion affinity chromatography (IMAC) through use of the batch binding method. Binding-resin 
(His-select Nickel Affinity Gel, Sigma-Aldrich) was used to purify the insoluble protein (see 
section 2.2.8) and was done under denaturing conditions as per the manufacturer’s 
instructions. This involved using 8M urea to solubilise the proteins and low pH to elute 
proteins from the resin. The equilibration buffer (1XPBS, 0.5M Nacl, 8M urea, pH8) and wash 
buffer (1XPBS, 0.5M Nacl, 8M urea, pH6.3) was used at a set pH, whereas the elution buffer 
(1XPBS, 0.5M Nacl, 8M urea) had a range of pH conditions for elution optimisation (pH6, pH5 
and pH4.5). The same procedure was followed for the negative control (empty E. coli vector). 
2.2.17 LARGE-SCALE AFFINITY PURIFICATION OF RECOMBINANT PLANT ANTIGEN.  
Purification of the recombinant N. benthamiana expressed antigen proteins was done using 
IMAC through use of a 5ml prepacked Nickel Sepharose™ High Performance column 
(HisTrap™ HP, GE Healthcare). The column was equilibrated with 5 column volumes (CV) of 
equilibration buffer (1XPBS, 0.5M NaCl, 8M urea, pH8). The column was then loaded with the 
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plant extract using a 150ml SuperLoop; this was followed by 10 CV washes using wash buffer 
(1XPBS, 0.5M NaCl, 8M urea, pH8). Elution of the recombinant protein was done over 20 CV 
of a linear gradient of elution buffer (1XPBS, 0.5M NaCl, 8M urea, 0.5M imidazole, pH8) from 
0%-100%, with the final elution step being 5 CV of 100% elution buffer. The ÄKTA Explorer™ 
Fast protein liquid chromatography (FPLC) system and UNICORN 4.11 software (GE 
Healthcare) were used. The fractions were stored at -20oC for later analysis. 
2.2.18 QUANTIFICATION OF AFFINITY-PURIFIED PROTEIN.  
Purified E. coli protein was quantified using the Bradford assay (as described in section 
2.2.12.) using a BSA standard.  Purified plant samples were quantified via gel densitometry 
(Syngene GeneTools image analysis software (version 3.07.03)) of western blots (section 
2.2.15) using purified plant produced scFv (CRAb-FM27) used as a standard curve (as 
described in Chapter 3).   
2.2.19 LYOPHILISATION.  
Purified plant produced 3B-O protein was concentrated by lyophilisation, where 1ml aliquots 
of the samples were placed in Eppendorf tubes and frozen at -80oC overnight. The tubes were 
then opened and covered with Parafilm (Parafilm M®, Bemis) in which pinholes were made. 
The samples were then placed into holding vessels and freeze dried overnight. The freeze-
dried contents of the tubes were stored at ambient temperature or reconstituted in 200µl of 
dH2O and stored at -20°C for later analysis.   
2.3 RESULTS 
2.3.1 INITIAL EXPRESSION OF 3ABC-O  
Initially the full length 3ABC-O gene was synthesised, cloned into the E. coli expression vector 
pProEX-HTb, and into the plant expression vectors pRIC3.0-HT and pTRAKc and tested for its 
ability to express recombinant 3ABC-O in N. benthamiana (by syringe infiltration) or in E. coli 
(by induction with IPTG).  Expression of 3ABC-O was tested for by screening both leaf samples 
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and partially purified E. coli extract samples by western blot using an anti-his antibody (not 
shown). However, no expression was observed, even after multiple attempts.  
2.3.2 GENE MODIFICATION 
It was hypothesised that the 3Cpro region of the polyprotein was possibly responsible for the 
lack of recombinant 3ABC-O expression due to it causing proteolysis of host cell proteins. It 
was therefore decided that modifications of the 3ABC-O gene were necessary to encourage 
expression. The first modification was to mutate and thereby abolish the active site of the 
3Cpro. The second was to remove the 3Cpro region by truncation of the polypeptide gene to 
yield 3AB and the third was to explore and test three new variants of 3ABC. 
2.3.2.1 Site-directed mutagenesis of 3ABC-O 
Substitution mutations were introduced into the 3Cpro region of the 3ABC-O gene with use of 
the primers and conditions mentioned in Table 2.2. The two mutations Cys142Ser and 
Cys163Gly are known to improve solubility and disrupt the active site, respectively. The 
mutations were designed such that they would include synonymous mutations for the 
addition of restriction sites TaqI and MnlI, respectively. These added RE sites were used to 
confirm successful site-directed mutagenesis mutation by restriction enzyme digest and 
analysis of the banding pattern by gel electrophoresis. Confirmation of a successful Cys142Ser 
substitution mutation would show the absence of a 431 bp fragment, whereas the presence 
of this band would indicate a lack of mutation (Figure 2.2 A). Confirmation of the Cys163Gly 
substitution mutation would show the absence of a 629 bp fragment and the presence of a 
462 bp fragment (Figure 2.2 B). The mutations in the gene were then further confirmed by 




2.3.2.2 Truncation of 3ABC-O 
Truncation of the 3ABC-O gene was achieved using PCR.  Amplification of 3ABC-O with primers 
and conditions in Table 2.3 resulted in the 3AB-O variant, seen as a 728 bp fragment during 
colony PCR (Figure 2.3).   
2.3.2.3 Synthesis of new variants 




Figure 2.2. 2.5% agarose gel displaying banding patterns of digested 3ABC-O gene to confirm mutations.  
(A) Banding pattern after TaqI digest to identify if Cys142Ser mutation is present (mutated 3ABC-O) and not present 
(unmutated 3ABC-O), if the 431bp band is visible. (B) Banding pattern after MnlI digest to identify if Cys163Gly mutation is 
present (mutated 3ABC-O) with the loss of the 431bp band or not present (unmutated 3ABC-O) with the 629bp band seen. 
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2.3.3 CONSTRUCT CONFIRMATION 
The five variations of the 3ABC gene were cloned into both the E. coli expression vector 
(pProEX-HTb) and plant expression vectors (pRIC3.0-HT and pTRAKc) (Table 2.4). Colony PCR 
was used to confirm successful cloning.  
2.3.3.1 Construct confirmation in E. coli expression vector 
The variant antigen genes were successfully cloned into the pProEX-HTb E. coli expression 
vector.  The following fragment sizes were observed, confirming successful cloning: 3ABC-O 
(1371 bp), mu3ABC-O (1371 bp), 3AB-O (728 bp), 3AB1-Arg, (809 bp) 3B-O (500 bp) and 
mu3ABC-A (1592bp) (Figure 2.3). Positive colonies were selected and RE digest and 
sequencing was used to further confirm successful cloning (not shown). 
2.3.3.2 Construct confirmation in plant expression vectors 
The five variants of the 3ABC polyprotein gene were subcloned into two plant expression 
vectors pRIC3.0-HT and pTRAKc-ERH. Confirmation of successful cloning and transformation 
into A. tumefaciens was achieved using colony PCR, with the use of vector specific primers 
(Table 2.5). Results from the screening of these colonies is shown in Figure 2.4, which shows 
appropriate band sizes for each gene in the different vectors:  pRIC3.0-HT-mu3ABC-O 
Figure 2.3. 1% agarose gel displaying E. coli colony PCR confirming pProEX-HTb vector with antigen gene inserts.  
 




(1528bp), pRIC3.0-HT-mu3ABC-A (1618bp), pTRAKc-mu3ABC-O (1593bp), pTRAKc- mu3ABC-
A (1586bp), pRIC3.0-HT-3AB-O (889bp), pRIC3.0-HT-3B-O (526bp), pRIC3.0-HT-3AB1-Arg 
(835bp), pTRAKc-3AB-O (954bp), pTRAKc-3B-O (494bp) and pTRAKc-3AB1-Arg (803bp). 
Positive clones were confirmed by RE digest using the same RE sites used for cloning (not 
shown).  
2.3.4 ANALYSIS OF ANTIGEN EXPRESSION  
Once positively transformed colonies with the five variants had been identified in the E. coli 
and plant expression vectors, expression was performed on a small scale. This was done in 
order to determine whether recombinant vectors were successfully expressing the antigen, 
and to the optimal conditions for large scale expression and extraction. 
2.3.4.1 Analysis of E. coli expressed antigens  
Detection of expressed recombinant protein was analysed by anti-his western blotting of 
protein extracts sampled at 1, 2 and 3 hours post induction with IPTG. Expression of 3ABC-O 
Figure 2.4. 1% agarose gel displaying Agrobacterium colony PCR confirming plant vectors with antigen gene inserts.  
 
A) mu3ABC-O and 3AB-O both within pRIC3.0-HT (1528bp and 889bp respectively) and pTRAKc (1593bp and 954bp 
respectively). B) mu3ABC-A, 3B-O and 3AB1-Arg within pRIC3.0-HT (1618bp, 526bp and 835bp respectively) and pTRAKc 
(1586bp, 494bp and 803bp respectively). 
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was not detected over 3 hours post induction. However, the mu3ABC-O gene which contained 
both mutations (Cys142Ser and Cys163Gly), was expressed in consistent amounts over 3 
hours as visualised by a 53KDa protein band (Figure 2.5). The 3AB-O variant was expressed 
and sampled over three hours (not shown) of which protein from the third hour after 
induction is shown in Figure 2.5 as a 35KDa band.  
Initially the mu3ABC-A, 3B-O and 3AB1-Arg E. coli constructs were successfully expressed and 
samples taken every hour for three hours after induction. Each of the constructs showed 
increasing amounts of protein over three hours (not shown). Figure 2.6 shows protein 
sampled 2 hours after induction for the three new variants, visualised in an anti-his western 
blot. The mu3ABC-A polyprotein is seen at 53KDa protein band in Figure 2.6, along with 
multiple lower bands. Expression of 3B-O protein is expected at 13KDa as indicated by the 
black arrow in Figure 2.6 but a second higher molecular weight band is seen at around 20KDa 
indicated by the blue arrow. The 3AB1-Arg protein was expected at around 24KDa but with a 
faint band seen at this position (Figure 2.6, black arrow). There are multiple bands seen in the 
3AB1-Arg expression lane, with the darkest band at around 30KDa. Figure 2.6 also shows the 
Figure 2.5. Western blot of E. coli expressed mutated and truncated 3ABC antigen displayed as an hourly time trial.   
Mutated antigen (Mu3ABC-O) and Non-mutated antigen (3ABC-O) expression shown over hours (h) 1, 2 & 3. Truncated 
variant (3AB-O) expression shown at the third hour. Marker (PageRuler™). Black arrows showing mu3ABC-O at 53KDa and 
3AB-O at 35KDa. Anti-his 1/2000. 
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lack of bands in the negative control lane, indicating no non-specific antibody binding. The 
multiple bands seen in Figure 2.6 are not observed in Figure 2.5, and is suspected to be due 
to the 6Xhis tag being located at both terminals of the mu3ABC-A, 3B-O and 3AB1-Arg 
proteins, which could influence expression, or if degraded would give a number of bands. 
2.3.4.2 Analysis of plant expressed antigens 
Transient expression of all constructs in plants on a small scale was repeated 3 times. Each of 
the pRIC3.0-HT and pTRAKc constructs were syringe-infiltrated at an OD600 of 0.5 or 1.0 into 
three plants. Leaf disks were sampled on days 1, 3 and 5 dpi and homogenised with both a 
denaturing (1XPBS + 8M urea) and native (1XPBS) buffer, separately. The samples were 
analysed by an anti-his western blot, using a crude E. coli sample of the cognate protein as 
the positive control and a crude leaf sample infiltrated with an empty pRIC3.0-HT or pTRAKc 
vector used as a negative control.  
Analysis of crude leaf extracts by western blot was done in order to determine the optimal 
day of harvest, optimal bacterial OD600 at which to infiltrate cultures and best extraction 
Figure 2.6. Western blot of E. coli expressed antigens (three new variants).  
Positive control (E. coli-expressed mu3ABC-O), Negative control (crude E. coli extract containing empty pProEX-HTb vector), 
Marker (Color Prestained protein standard), mutated 3ABC-A (53KDa), truncated 3B-O (13KDa) and 3AB1-Arg (24KDa) 
expression at 2 hours. Black arrows showing position of proteins and blue arrow indicating ≈20KDa upper band for 3B-O 
protein. Anti-his 1/2000 
45 
 
buffer to use. To ensure a true comparison between the samples, equal amounts of total 
protein were loaded into each well. A Bradford assay was used to determine total protein in 
each of the samples.   
Analysis of expression of mu3ABC-O, 3AB-O and 3AB1-Arg from both pTRAKc and pRIC3.0HT 
vectors showed no expression (not shown). This was observed for each biological repeat 
experiment.  
Expression of mu3ABC-A and 3B-O, however, was successful. The small-scale time trials 
showed mu3ABC-A expression was highest with the pTRAKc expression vector at 3 days post 
infiltration at an OD600 1.0 as the most dense 53KDa band is seen in that lane (Figure 2.7 B). 
Multiple bands were seen for the pTRAKc-mu3ABC-A construct expression (Figure 2.7 B, 
orange, blue and red arrows), which are suspected to be due to proteolytic cleavage by native 
plant proteases.  No expression was seen with the pRIC3.0-HT vector (Figure 2.7 A). 
Figure 2.7. Western blot displaying small scale time trial of plant-expressed mu3ABC-A.  
(A) pRIC3.0-HT-mu3ABC-A and (B) pTRAKc-mu3ABC-A construct sampled. Negative control (crude leaf extract infiltrated 
with empty pRIC3.0-HT or pTRAKc vector), Positive control (Crude E. coli expressed mu3ABC-A), Marker (Color Prestained 
protein standard). Days 1, 3 and 5 post-infiltration, each with an OD600 of 0.5 and 1 tested. Black arrows indicating position 
of mu3ABC-A protein (53KDa), orange arrow indicates possible degradation within the 3A region of the polyprotein (35KDa), 
blue arrows indicating processed polyprotein being cleaved within the 3B region of mu3ABC-A (B3C= 26, B2B3C= 28 and 
B1B2B3C= 30 KDa) and red arrow indicating 3Cpro alone (≈24KDa). 
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The small-scale time trials conducted for 3B-O expression showed the highest levels of 
expression when using the pRIC3.0-HT vector, with no protein bands observed when using 
the pTRAKc vector (Figure 2.8 A and B respectively). The highest expression levels of 3B-O 
were observed at 5 days post infiltration (dpi) using an infiltration culture OD600 of 1.0, as the 
protein bands were more dense in those particular lanes (Figure 2.8 A). The 3B-O protein is 
expected to be 13KDa, which is seen as the lower band in Figure 2.8 A, but again a second 
band is also seen at a higher molecular weight at around 20KDa. This upper band is also seen 
in the E. coli positive control and is suspected to be an alternative product due to post 
translational modifications. The plant-produced 3B-O protein has greater upper band density 
than the lower, which might indicate that plant expression might favour the higher molecular 
weight modification.  
Extraction of both the mu3ABC-A and 3B-O proteins was only successful using a denaturing 
extraction buffer (1XPBS + 8M urea), as no protein was seen when using 1XPBS only (not 
shown). Therefore, the NSPs appear to be insoluble    
 
Figure 2.8. Western blot displaying small scale time trial of plant-expressed 3B-O.  
(A) pRIC3.0-HT-3B-O and (B) pTRAKc-3B-O constructs sampled. Negative control (crude leaf extract infiltrated with empty 
pRIC3.0-HT or pTRAKc vector), Positive control (Crude E. coli-expressed 3B-O), Marker (Color Prestained protein 
standard). Days 1, 3 and 5 post-infiltration, each with an OD600 of 0.5 and 1 tested. Black arrows indicating position of 
3B-O double band (lower band 13KDa, upper band ≈20KDa). 
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2.3.5 LARGE SCALE AFFINITY PURIFICATION  
Expression of all five variants of the 3ABC polypeptide was successful in E. coli, but only the 
3B-O and mu3ABC-A variants were expressed in plants. The plant expressed 3B-O protein 
showed higher expression than the mu3ABC-A protein and with less degradation, and 
therefore it was decided that the 3B-O protein would be continued with. Large scale 
expression of 3B-O was carried out using E. coli and N. benthamiana, using the optimal 
conditions determined in section 2.3.4, so that optimal purification conditions could be 
determined and 3B-O could be purified.   
2.3.5.1 Purification of E. coli expressed 3B-O 
The pProEX-HTb-3B-O glycerol stock was grown up, induced and cells harvested 3 hours post 
induction. Purification of the E. coli-expressed antigen was achieved using the batch binding 
method, to generate sufficient recombinant protein for functionality testing. The fractions 
collected during purification were analysed on an anti-his western blot as well as a Coomassie 
Figure 2.9. Batch binding purification of E. coli-expressed 3B-O, fractions analysed. 
(A) Anti-his 1/2000 western blot and (B) Coomassie stained SDS-PAGE. Marker (Color Prestained protein standard), crude 
(5ul cell culture pre-purification), FT (Flow Through), W1 (Wash 1), W2 (Wash2), E1 (Elution 1, pH6), E2 (Elution 2, pH 5), E3 
(Elution 3, pH 4.5). Elution of 2ml was done and 30µl loaded into each lane. The black arrows indicate the upper (≈20KDa) 
and lower (13KDa) 3B-O protein bands. 
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stained gel (Figure 2.9 A&B respectively). The western blot showed the 3B-O protein present 
in the flowthrough (FT), as the common double band is observed, but very little seen in the 
wash fractions (W), with only the lower band being faintly seen. Decreasing the pH of the 
buffers was used to elute the protein from the resin. To determine the optimal pH for elution 
a range of pH elution buffers were tested. The E1 sample showed very little 3B-O elution, seen 
by the faint band in Figure 2.9 A, which had a pH of 6. The E2 sample showed a dark band at 
13KDa and a very faint band at ≈20KDa, with a similar result observed for the E3 sample. This 
indicated that the elution of 3B-O was highest at a pH 5 (E2) and pH 4.5 (E3). The same 
samples were analysed by Coomassie-staining (Figure 2.9 B), which showed a decrease in total 
protein between the crude and eluted fractions, indicating purification had been successful. 
The western blot also showed that once the protein had been eluted from the resin, the lower 
band seemed denser compared to the upper band.  
2.3.5.2 Purification of plant expressed 3B-O 
Purification of N. benthamiana-produced 3B-O protein using the pRIC3.0-HT-3B-O construct 
was done using the ÄKTA system. In order to obtain a substantial working volume for 
purification, a large amount of protein was required. Therefore, the construct was vacuum 
infiltrated into 12 plants at the optimal conditions determined during the small-scale testing 
(see 2.3.4.2.).  
The ÄKTA system displays absorbance readings at 280nm on a chromatogram. The 
chromatogram for the purification of 3B-O is shown in Figure 2.10, which indicated a high 
protein absorbance in the flowthrough fractions (fractions 1-18) and then a considerable drop 
during the wash phase (fractions 19-27). The initial absorbance was due to the high 
concentration of plant proteins present in the sample. The appearance of a second high 
absorbance peak was observed in the elution fractions (fractions 29-32), which smoothed out 
into the shoulder (fractions 33-35). The increasing imidazole gradient, during elution, 
continued up to fraction 48 and then plateaued from fraction 49-53 with no other peaks of 
absorbance seen.  
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The successful purification of the 3B-O protein was confirmed by analysing the ÄKTA fractions 
on an anti-his western blot and Coomassie stained gel (Figure 2.11 A & B respectively). The 
western blot showed that minimal levels of 3B-O protein was captured in the flowthrough 
and none was present in the wash fractions. Analysis of the eluted fractions within the second 
absorbance peak (E29-35), indicated that the 3B-O protein was present in that peak as well 
as within the shoulder of it (Figure 2.11 A, black arrows). The darker bands are seen in 
fractions E31 and E32, indicating that this was where the majority of the protein was being 
eluted. The common double band is seen within the elution fractions, with the upper 
(≈20KDa) band appearing to be the darkest and most prominent.  
The Coomassie stained gel (Figure 2.11 B) shows the total protein within the fractions and 
gives an estimate of how pure the samples were. The flowthrough fraction (FT8-10) showed 
a smear suggesting a large amount of various proteins were present. This correlates well with 
Figure 2.10. Chromatogram trace of ÄKTA purification of N. benthamiana-produced 3B-O.  
Blue line indicating Absorbance at 280nm (Y axis), green line showing gradient increase of elution buffer as a percentage of 
0.5M Imidazole. X axis indicating fractions of Flow through (1-18), Wash (19-27) and Elution (28-51). 
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the initial large peak seen in the chromatogram in the same fractions. The eluted fractions 
(E30-32), show a substantial amount of other high molecular weight plant proteins being 
present (Figure 2.11 B, red arrow). Therefore, the high absorbance observed in the second 
peak is probably due to the presence of native plant proteins and does not represent the level 
of 3B-O protein alone. The Coomassie stained gel indicates that the eluted fractions collected 
across the second peak contain co-eluting contaminating proteins and therefore show that 
these fractions do not consist purely of the 3B-O protein. However, a reduction of the 
contaminant in the E33-35 fractions (shoulder of second peak) was also seen, indicating that 
these might be the purest of the fractions.     
2.3.6 QUANTIFICATION 
Once purification of the 3B-O protein was completed, the eluted (semi-pure) fractions were 
quantified. The E. coli expressed 3B-O was quantified using a Bradford assay. The plant 
purified 3B-O preparation contained levels of native plant proteins in the elution fractions 
Figure 2.11. Fractions from the ÄKTA purification of N. benthamiana-produced 3B-O.  
(A) Western blot Anti-his 1/2000 and B) SDS-PAGE coomassie stained. Marker (Color Prestained protein standard), Flow Through 
fractions (FT 8-10), Wash fractions (W 22-24), Elution fractions (E 29-50). Black arrows showing position of purified double 3B-
O protein (upper ≈20KDa and lower 13KDa bands) and the red arrow indicates high molecular weight contaminant (≈55KDa). 
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and therefore total protein via a Bradford assay was considered to be inaccurate. Therefore, 
a western blot was run and densitometry was used for quantification of plant 3B-O. 
2.3.6.1 Quantification of E. coli purified 3B-O  
The purified E. coli 3B-O protein was quantified by Bradford assay, which gave a concentration 
range of 0.095µg/µl to 0.102µg/µl (not shown) at a volume of 2ml. 
2.3.6.2 Lyophilisation and quantification of plant purified 3B-O 
The elution fractions E30-35 contained the 3B-O protein but at very low levels, as seen in the 
western blot (Figure 2.11 A). Accordingly, the fractions were subjected to lyophilisation 
(freeze drying) in order to concentrate the protein once reconstituted in a 1/5th of the starting 
volume (not shown). The fractions were then quantified using densitometry by western blot, 
which indicated that fraction E31 gave the highest concentration of 0.0057µg/µl at a volume 
of 5ml. 
2.4 DISCUSSION  
As most studies of FMDV non-structural protein expression have been done in an E. coli 
system, I did the same, both so as to have a positive control, and to have proteins for 
comparison to the plant made proteins. However, preliminary work done to express FMDV 
3ABC-O in both N. benthamiana and E. coli was not successful as seen by a complete absence 
of protein bands of 53kDa in size on western blots. This was surprising, as the FMDV 3ABC 
polyprotein has previously been expressed in E. coli (Clavijo et al., 2004; Nanni et al., 2005; 
Jaworski et al., 2011; Gao et al., 2012; Sharma et al., 2012; Mohapatra et al., 2014) and insect 
cells (Sørensen et al., 1998; Chung et al., 2002; Srisombundit et al., 2013).   
The 3C region of the FMDV genome encodes a serine protease (3Cpro), which is responsible 
for proteolytic cleavage of the viral encoded polyprotein into its individual structural and non-
structural proteins (Vakharia et al., 1987; Clarke and Sangar, 1988). It has been shown that 
3Cpro is responsible for cleavage of host cell eIF-4A (RNA helicase) as well as the histone H3, 
which is responsible for shutting down of host transcription (Falk et al., 1990; Belsham, 
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McInerney and Ross-Smith, 2000). It is therefore possible that in my case, transient 
expression of the 3ABC polyprotein could have resulted in inhibition of host cell transcription 
and inhibition of recombinant expression in N. benthamiana and E. coli as a result of the 
activity of 3Cpro.  
It was thus decided to manipulate the 3ABC gene and mutate/remove the 3C coding region 
in order to encourage expression of this protein. Sariya et al. (2011) showed that disrupting 
the active site of the 3Cpro enhances expression of the full 3ABC polypeptide in E. coli. Thus, 
in this work, I introduced two substitution mutations (Cys142Ser & Cys163Gly) into 3ABC to 
encourage recombinant expression (Sariya et al., 2011; Srisombundit et al., 2013). The 
addition of the first mutation (Cys142Ser) alone did not enhance expression (not shown). It 
was only after the addition of the second mutation (Cys163Gly), which is responsible for 
disrupting the active site of the 3C protease, that expression was observed (Figure 2.5).  
In addition to mutating 3ABC, the 3C coding region was removed to create a truncated version 
(3AB-O). The expression of the truncated polyprotein was successful (Figure 2.5, lower band), 
and confirmed the 3C protease involvement in reducing expression.   
In addition to the above variant genes tested for expression of recombinant protein, three 
new genes were synthesised: these were mu3ABC-A, 3B-O and 3AB1-Arg. This was done to 
give a greater variety, to explore the possibilities of a better antigen option, as well as to 
increase the chances of successful expression. Investigation into the expression of both 
serotype O and A non-structural proteins was done as infected animal serum from these two 
serotypes had been obtained for testing purposes. The selection of the non-structural 
proteins to be tested was also influenced by the competing scFv to be used, as the CRAb-
FM27 scFv (discussed in Chapter 3) is known to bind epitopes found within the 3B region of 
the polypeptide (Foord et al., 2007). Therefore, the NSPs to be investigated would have to 
contain the 3B region. The 3ABC full length polyprotein had previously been shown as the 
best NSP for a FMDV diagnostic reagent (Mackay et al., 1998). It was for this reason that the 
3ABC-O (serotype O) and 3ABC-A (serotype A) were chosen. The truncated 3AB-O gene was 
also a candidate for study, as a difference in expression between the mu3ABC-O might be 
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seen as a result of the removal of the 3C protease portion. The 3AB protein has also been 
used to successfully distinguish infected from vaccinated animal serum in an I-ELISA (Sørensen 
et al., 1998; Chung et al., 2002). The 3B-O gene had been selected as it has previously been 
shown to differentiate infected from vaccinated serum just as effectively as the full length 
polyprotein (Gao et al., 2012). The 3AB1 protein has also been successfully used as a DIVA 
reagent (Nanni et al., 2005; Jaworski et al., 2011) and therefore was also chosen.  
Constructs encoding each of the 5 genes (mu3ABC-O, 3AB-O, mu3ABC-A, 3B-O and 3AB1-Arg) 
resulted in the appropriate recombinant protein expression using an E. coli expression system 
(Figures 2.5 and 2.6). It was noted, however, that additional bands were visualised in the lanes 
containing proteins encoded by mu3ABC-A, 3B-O and 3AB1-Arg. It is unclear as to why this is, 
but is hypothesise that it could be because mu3ABC-A, 3B-O and 3AB1-Arg are cloned in such 
a way that the resulting recombinant protein has both an N and C-terminal 6Xhis-tag. It is 
thought that with recombinant proteins having a histidine tag at either end, cleavage or 
degradation anywhere in the centre of the protein would lead to twice as many bands 
compared to proteins with just one 6Xhis-tag, and shown at different sizes. This is seen in the 
anti-his western blot in Figure 2.6, where the positive control (mu3ABC-O) which contains 
only one 6Xhis-tag shows 8 distinct bands, whereas the mu3ABC-A which has a 6Xhis-tag at 
both ends of the protein has 16 bands. The multiple bands observed in Figure 2.6, thought to 
be from protein degradation, could be a result of storing the samples at -20°C and not 
analysing it fresh, as done for the samples in figure 2.5.    
The same 5 genes cloned into plant expression vectors pTRAKc and pRIC3.0-HT and infiltrated 
into N. benthamiana did not all result in transient expression of recombinant protein. Only 
the mu3ABC-A and 3B-O proteins were successfully expressed (Figures 2.7 and 2.8 
respectively, black arrows). It was interesting to see that the vector which had the highest 
expression levels of 3B-O based on the density of the protein bands in a western blot, was 
pRIC3.0-HT - whereas it was the pTRAKc vector for mu3ABC-A. The N. benthamiana-produced 
mu3ABC-A protein showed multiple bands in the anti-his western blot (Figure 2.7 B, orange, 
blue and red arrows). It is suspected that the mu3ABC-A protein could have undergone 
proteolysis during expression, resulting in multiple bands. Naturally, it is the viral 3Cpro (serine 
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protease) that cleaves the polyprotein into individual mature proteins during processing at 
various sites to produce 3A, 3B1, 3B2, 3B3 and 3C proteins (Figure 1.2). With the 3Cpro region 
of the polyprotein being deactivated by mutation, it has been hypothesised that native plant 
serine proteases (Pillay et al., 2013) might be processing the polyprotein in a similar way. If 
this were the case and cleavage were to take place at the same sites of the polyprotein as it 
would naturally, multiple proteins would be observed on an anti-his western blot. The 6Xhis 
tag is fused to the C-terminus of the recombinant mu3ABC-A protein, and thus only a select 
few proteins would be observed when cleaved. The 3Cpro protein, if cleaved from the 
polyprotein alone, would be seen at ≈24KDa as indicated by the red arrow in Figure 2.7 B. The 
3B region is made up of three segments (B1, B2 and B3) and depending on where proteolysis 
takes place, it would either give the B1B2B3C (≈30KDa), B2B3C (≈28KDa) or B3C (≈26KDa) 
indicated by the blue arrows in Figure 2.7 B. Proteolysis within the 3A region of the 
polyprotein could explain the presence of a ≈35KDa band (Figure 2.7 B, orange arrow) 
appearing below the full mu3ABC-A polyprotein but above the B1B2B3C band. If the hypothesis 
of native plant serine proteases processing the non-structural proteins of the virus is true, this 
might explain why expression for the mu3ABC-O, 3AB-O and 3AB1-Arg proteins are not 
observed - if these proteins were more susceptible to proteolysis than the mu3ABC-A or 3B-
O proteins. If the same processing, but to a lesser degree, is taking place for the 3B-O protein 
individual proteins (B1, B2 and B3) would not have been seen as they could have migrated off 
the SDS-PAGE due to their low molecular weight. The expression of the NSPs did not allow for 
the retention of the recombinant proteins in the ER, which has shown to protect against 
proteolysis, and which could have improved the expression levels and quality of these 
proteins. However, this was not explored due to time constraints. The extraction of these 
NSPs was achieved using 8M urea, which suggests that these proteins are insoluble. It is 
known that the 3A protein associates with intracellular membranes, and which is thought to 
anchor the replication complex of picornavirus to the ER membrane (Weber et al., 1996; Suhy, 
Giddings and Kirkegaard, 2000; O’Donnell et al., 2001), therefore, it is suspected that the NSP 
variants which included the 3A region would be insoluble and difficult to extract. Extraction 
using 8M urea showed to effectively solubilise the proteins and hence no other detergents 
were investigated.     
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The 3B-O protein was chosen to continue with as it showed dense protein bands in a western 
blot (Figure 2.8 A), indicating good expression and possibly less degradation, in comparison 
to the mu3ABC-A protein (Figure 2.7 B). The pRIC3.0-HT-3B-O construct encoding the 3B-O 
gene was expressed on a larger scale in plants in order to develop a purification protocol for 
producing sufficient amounts to test in an ELISA. This was done by nickel affinity 
chromatography using the ÄKTA fast protein liquid chromatography system. 3B-O was 
successfully purified to a certain degree although analysis of fractions collected indicated the 
presence of a co-eluting contaminant. It is suspected that this high molecular weight 
contaminant (≈55KDa) is RuBisCO, the most abundant protein found in plants (Portis Jr, 2001). 
The addition of imidazole in the binding buffer is known to reduce non-specific binding of 
contaminants to the nickel resin during purification. However, due to the 3B-O protein eluting 
very early on at a low concentration of imidazole (0.05M), imidazole in the binding buffer 
might have resulted in the loss of 3B-O. This makes it difficult to isolate the 3B-O protein from 
other native plant proteins, which share a similar affinity towards the nickel resin. It is possible 
that RuBisCO has a low affinity for the nickel resin similar to that of the his-tag of the 3B-O 
protein, resulting in both proteins eluting at a similar imidazole concentration. The lowering 
of the imidazole gradient or making it a more gradual increase of imidazole during elution is 
known to help separate proteins with slightly similar affinity towards the resin. This technique 
separates protein peaks that are close together but it seems even when this was done, the 
contaminant again co-eluted even within the later elution fractions (E33-E35). This indicated 
less contaminating protein but also less 3B-O protein (Figure 2.11 A & B). Therefore, it is 
hypothesised that there might be a more direct interaction taking place between RuBisCO 
and the 3B-O protein, therefore resulting in co-elution of the two proteins. However, possible 
pre-purification techniques such as ammonium sulphate precipitation, pH precipitation or 
protamine sulphate precipitation (Kim et al., 2013) could be employed to assist in the removal 
of RuBisCO and other native plant proteins prior to IMAC. However, these techniques were 
not explored due to time constraints as well as, if there is an association or an affinity 
between RuBisCO and 3B-O (as is suspected during the elution of 3B-O from the nickel 
column due to RuBisCO co-eluting along with it (figure 2.11)), RuBisCO might draw the 
3B-O protein out of solution as it precipitated.  
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3B-O protein in the eluted fractions was quantified via western blot densitometry as the 
concentrations were too low for quantification using gel densitometry. An attempt to 
concentrate these fractions was made by freeze drying and resuspending in 1/5th of the initial 
volume. Samples analysed on a western blot indicated that freeze drying did not have a 
degrading effect on the protein as only the two bands were seen as previously shown (not 
shown). The concentration of the 3B-O protein was still not sufficient to detect the protein by 
Coomassie and therefore densitometry was done as a western blot. The standard used for 
quantification was the plant expressed scFv (CRAb-FM27 described in Chapter 3) as this was 
expressed in high enough quantities to be well quantified by densitometry using a Coomassie-
stained gel. The scFv was also chosen as the standard as it had the same single C-terminal 
6Xhis-tag as the 3B-O protein and therefore was more comparable. Yields of 3B-O protein 
from the large-scale purification were calculated to be around 6.13µg per gram of infiltrated 
leaf material and a concentration range between 0.0042 µg/µl to 0.0057µg/µl after 
purification. The total 3B-O protein within the fraction was compared to the total 3B-O 
protein within the crude extract (crude plant extract taken before purification) and showed a 
58% recovery of the 3B-O protein after purification.  
The production of 3B-O protein in E. coli was also scaled up which was then purified in order 
to have a comparison for functionality of plant-produced 3B-O in ELISAs. The E. coli-produced 
3B-O was purified by batch binding, which showed less co-eluting native proteins than that 
seen in the plant purified 3B-O, when comparing the Coomassie staining in Figure 2.9 B and 
Figure 2.11 B respectively. It was for this reason that quantification of E. coli 3B-O was done 
using the Bradford assay, which gave a concentration range of 0.095µg/µl to 0.102µg/µl. The 
E. coli-expressed and purified 3B-O protein was not high enough to perform densitometry in 
the form of a Coomassie-stained gel due to the bands not being visible. The same was not 
possible for densitometry as a western blot as the protein contained two his-tags, which 
would not be comparable to a standard that only contained one. 
The N. benthamiana and E. coli-produced 3B-O is seen as a double band in an anti-his western 
blot and it was first thought to be due to dimer formation. This was not the case as a dimer 
of the 13KDa 3B-O protein would result in a 26KDa band, but the upper band was around 
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20KDa. It is possible that the two bands might be different post-translational forms of the 
same protein. It has been shown that both prokaryotes and eukaryotes have the ability to 
post-translationally modify proteins (Dell et al., 2010; Grangeasse, Stülke and Mijakovic, 
2015). Glycosylation of proteins can increase the molecular weight and therefore show 
increased sizes of proteins on SDS-polyacrylamide gels.  It is possible that the higher molecular 
weight band represents a more glycosylated form of the protein. However, when the 3B-O 
sequence was run through an in-silico prediction server for N-Glycosylation sites (Gupta, Jung 
and Brunak, 2004) no glycosylation sites were identified. Lysine acetylation is one of the major 
post-translational modifications in chromatin remodelling, activation of transcription factors 
and metabolic enzymes. It has also recently been found that lysine acetylation takes place 
within other non-histone proteins within both prokaryotic and eukaryotic systems (Ouidir, 
Kentache and Hardouin, 2016), particularly in E. coli and plants (Nallamilli et al., 2014).  When 
the 3B-O sequence was run through a lysine acetylation prediction site (Xue, Li and Yao, 2006), 
it showed many internal lysine sites that are susceptible to acetylation. It has also been shown 
that acetylation of proteins has an effect on their size and increases their apparent molecular 
weight (Guan et al., 2010). It is possible that in this case the 3B-O protein has undergone 
internal lysine acetylation, which has caused an increase in its size and the appearance of two 
bands. It has also been noted that the N. benthamiana-produced 3B-O protein gave a darker 
upper (≈20KDa) band when compared to the E. coli expressed 3B-O protein, which gave a 
darker lower (13KDa) band (Figure 2.8 A). This might be due to the extensive post-
translational modifications or the high level of acetylation that take place in plants which is 
not seen to the same extent in bacteria.     
In summary, the expression and purification of the 3B-O protein was successful in both the N. 
benthamiana and E. coli systems. This antigen was then tested for its ability to distinguish 






EXPRESSION AND PURIFICATION OF A SINGLE-CHAIN VARIABLE 
FRAGMENT MONOCLONAL ANTIBODY IN E. COLI AND N. 
BENTHAMIANA  
3.1 INTRODUCTION 
The diagnosis of FMDV, for which there is a continual requirement worldwide, is often done 
using serological analyses. These methods use structural and non-structural proteins (SP and 
NSP) purified from the virus in an ELISA format in order to either detect serotype-specific 
antibodies, or to distinguish serum between infected and vaccinated animals. The use of a 
competitive-ELISA (C-ELISA) with these viral proteins allows for a more sensitive analysis that 
can be performed on a wide range of animal species. This is due to specific competing 
antibodies being raised towards the viral proteins which are used in the ELISA, which 
therefore only requires detection of a single antibody during analysis. The competing 
antibodies can be whole immunoglobulin (Ig) molecules or recombinant single chain variable 
fragments (scFvs). The disadvantage of antibody production in hybridoma cell lines is that it 
is often a lengthy and expensive process that requires the use of animals. The advances in 
recombinant expression and phage display for expression of scFvs, has significantly reduced 
both the time and cost necessary for production of monoclonal antibodies. The expression of 
recombinant full length antibodies (IgG and IgA) and scFvs in a plant system has been shown 
to be highly successful and an economically viable method of antibody production when 
compared to mammalian cell culture (Daniell, Streatfield and Wycoff, 2001; Nandi et al., 
2016). The use of plants for the expression of immunoglobulins has shown a significant 
reduction in the cost of production from USD1000/gram for cell culture (hybridoma), to 
USD50/gram in plants (Daniell, Streatfield and Wycoff, 2001). 
Foord et al. (2007) identified a scFv isolated from a chicken phage display library that is able 
to bind to the 3ABC NSP of FMDV, strain O1K. The chicken recombinant antibody foot-and-
mouth clone 27 (CRAb-FM27) scFv was identified as having specificity for 3ABC and was 
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shown to bind epitopes found on the 3B region of the polypeptide. Recombinant CRAb-FM27 
was subsequently produced in an E. coli expression system from which it was purified and 
shown to work effectively as a competing agent in a C-ELISA to differentiate between FMDV 
infected and vaccinated animals (Foord et al., 2007). 
This Chapter describes the transient expression of CRAb-FM27 in N. benthamiana as a 
possible reagent for use in a C-ELISA for FMDV diagnosis, and as a cheaper alternative to E. 
coli expression. CRAb-FM27 was synthesised and cloned into the pTRAKc-ERH non-replicating 
plant expression vector in 2 different ways: one, so as to direct the scFv into and retain it in 
the endoplasmic reticulum (ER); the second, to direct it into the ER and subsequently allow it 
to be secreted into the apoplastic space of the plant cell. Previous work has shown that ER 
retention has  improved the yields of scFv expression (Schouten et al., 1996), as has secretion 
into the apoplast (Fischer et al., 1999). It was also thought that extraction of the scFv from 
the apoplastic space would be easier for purification purposes due to the reduced number of 
contaminating proteins in this compartment. 
Expression of CRAb-FM27 has previously been achieved only in an E. coli system (Foord et al., 
2007), and its expression in a plant system would be novel.  This Chapter also describes the 
expression of the same scFv in E. coli, which was done in parallel in order to generate a 
positive control for the plant expression analysis experiments, and to be used as a comparison 
for functionality testing in an ELISA of the plant expressed scFv, described in Chapter 4. 
3.2 MATERIALS AND METHODS 
3.2.1 PLASMID AMPLIFICATION AND ISOLATION.  
This was carried out as described in section 2.2.1.  
3.2.2 CONSTRUCT DESIGN AND SYNTHESIS.  
The CRAb-FM27 gene sequence was obtained from Foord et al. (2007) and was codon 
optimised for Nicotiana benthamiana, synthesised and cloned into pUC57 by GenScript 
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(China). It was designed to have an NcoI restriction site at the 5’ end and then two subsequent 
NotI and XhoI sites at the 3’end, with a 6xhis tag located between them. An XbaI site was 
placed at the extreme 3’ end after the XhoI site.   
3.2.3 CLONING STRATEGY AND SUBCLONING.  
The cloning strategy for the CRAb-FM27 gene was designed so as to generate two different 
plant constructs. The gene was digested and ligated into the pTRAKc-ERH expression vector 
using the NcoI and NotI sites in order to excise the 6xhis tag from the 3’ end of the gene but 
to retain the  6xhis tag and SEKDEL signal in the vector. This generated the pTRAKc-ERH-CRAb-
FM27 construct which encoded a 3’ 6xhis tagged protein, which was intended to be retained 
within the endoplasmic reticulum (ER) as a result of the presence of the SEKDEL signal. The 
second construct involved digesting the CRAb-FM27 using NcoI and XbaI restriction sites and 
ligation into the pTRAKc-ERH expression vector. This resulted in the removal of the 6xhis tag 
and SEKDEL signal from the vector but the retention of the 3’ 6x his tag within the gene. This 
generated the pTRAKc-A-CRAb-FM27 construct which encoded a 3’ 6xhis tagged protein that 
would not be retained within the ER. 
CRAb-FM27 was also cloned into the E. coli pProEX-HTb expression vector. This was achieved 
using the NcoI and XhoI RE sites which resulted in the gene having a 6xhis tag at both the 5’ 
end (retained within vector) and 3’ end (retained within gene).  
The cloning protocol was carried out as described in section 2.2.5.  
3.2.4 RECOMBINANT PLASMID CONFIRMATION.  
This was carried out as described in section 2.2.6.  Table 2.5 indicates the primers and cycling 
conditions used in colony PCR.  
3.2.5 E. COLI EXPRESSION OF RECOMBINANT PROTEIN.  




3.2.6 RECOMBINANT E. COLI PROTEIN EXTRACTION.  
The BugBuster™ protein extraction protocol was carried out as described in section 2.2.8 but 
only the soluble fraction was kept.  
3.2.7 A. TUMEFACIENS TRANSFORMATION.  
The pTRAKc-ERH-CRAb-FM27 and pTRAKc-A-CRAb-FM27 constructs were transformed into A. 
tumefaciens using the same protocol as described in section 2.2.9. 
3.2.8 A. TUMEFACIENS-MEDIATED TRANSIENT EXPRESSION.  
The pTRAKc-ERH-CRAb-FM27 and pTRAKc-A-CRAb-FM27 constructs were transiently 
expressed on a small scale and large scale using the protocols described in section 2.2.10. 
3.2.9 RECOMBINANT PLANT PROTEIN EXTRACTION.  
Extraction of proteins from leaves infiltrated with pTRAKc-ERH-CRAb-FM27 and pTRAKc-A-
CRAb-FM27 was done as described in section 2.2.11, with the exception of only extracting the 
soluble fraction with extraction buffer (1XPBS, pH7.4). 
Apoplast extraction of the CRAb-FM27 protein was done from leaves infiltrated with both 
constructs. Once the two constructs had been vacuum infiltrated into three plants each, the 
whole leaves were harvested on day 3 post infiltration. Equal amounts of leaf biomass from 
each construct was weighed out and submerged in extraction buffer (1XPBS). The extraction 
buffer was infiltrated into the apoplastic space using a vacuum as described in section 2.2.10. 
The leaves were dabbed dry, rolled up and placed into 20ml syringe barrels (without 
plungers). Handling of the leaves was carefully done so as to limit damage and rupturing of 
the cells within the leaf. These leaf filled syringes were placed into 50ml Falcon tubes which 
facilitated a gap between the end of the syringe and the bottom of the tube. The removal of 
the extraction buffer from the apoplastic space was achieved by centrifugation (300xg) for 30 
minutes. This was repeated until the leaves appeared to be dry and the apoplastic extract was 
collected at the bottom of the tubes. Extracts were stored at -20oC for later analysis.  
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3.2.10 BRADFORD ASSAY.  
This was performed as described in section 2.2.12. 
3.2.11 SDS-PAGE.  
This was performed as described in section 2.2.13. 
3.2.12 COOMASSIE BLUE STAINING.  
This was performed as described in section 2.2.14. 
3.2.13 WESTERN BLOTTING.  
The same procedure was carried out as in section 2.2.15. Western blots carried out for the 
detection of the scFv were done using two different primary antibodies. 1) The anti-his 
antibody (Mouse anti-his (1/2000) (Bio-Rad, USA, #MCA1396)) along with the secondary 
conjugate antibody (Goat Anti-mouse Alkaline phosphatase (1/10000) (Sigma-Aldrich, USA, 
A3562)) was used for the detection of the 6Xhis tag on the recombinant protein. 2) The anti-
chicken alkaline phosphatase conjugate (Anti-chicken IgY (IgG) (whole molecule)-Alkaline 
Phosphatase, Sigma-aldrich) was used for the direct detection of the chicken recombinant 
antibody Foot and mouth 27 (CRAb-FM27) scFv being expressed. 
3.2.14 BATCH BINDING PURIFICATION OF RECOMBINANT E. COLI SCFV.  
This was performed as described in section 2.2.16. The soluble fraction from section 3.2.6 was 
subjected to purification and was done so under native conditions as per the manufacturer’s 
instructions. The equilibration and wash buffers were the same and consisted of 1XPBS, 0.5M 
NaCl at a pH7.4. The elution buffer used consisted of 1XPBS, 0.5M NaCl, pH7.4 with four 
different imidazole concentrations, which were used to identify optimal elution buffer 
conditions. The range of imidazole concentrations were 0.01M, 0.1M, 0.25M and 0.5M for 
each elution buffer used. The elution process started with the elution buffer with the lowest 
imidazole concentration and then sequentially increased. The fractions collected were stored 
at -20oC for later analysis. 
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3.2.15 LARGE-SCALE AFFINITY PURIFICATION OF RECOMBINANT PLANT-PRODUCED SCFV.  
The procedure was followed as described in section 2.2.17. The buffers used were the same 
but lacked 8M urea. 
3.2.16 QUANTIFICATION OF AFFINITY-PURIFIED PROTEIN.  
The quantification of the purified E. coli protein was quantified using the Bradford assay (as 
described in section 2.2.12.) using a BSA standard.  
The purified plant protein samples were quantified via gel densitometry using Syngene 
GeneTools image analysis software (version 3.07.03). The samples were separated by SDS-
PAGE and stained using Coomassie blue and quantified against a BSA standard curve (0.125, 
0.062, 0.031 and 0.015 mg/ml).  
3.2.17 GLYCO-PROFILING OF PLANT PRODUCED SCFV.  
The purified plant scFv was lyophilised as described in section 2.2.19 and sent to the 
Department for Chemistry, Division of Biochemistry at the University of Natural Resources 
and Life Sciences, Vienna (BOKU) for glycoanalysis. Analysis by liquid chromatography- 
electrospray ionization-mass spectrometry (LC-ESI-MS) of reduced glycans using PNGase A 









3.3.1 E. COLI-EXPRESSION AND PURIFICATION OF CRAB-FM27 SCFV 
3.3.1.1 Construct confirmation 
The CRAb-FM27 gene was successfully digested from the pUC57 vector and ligated into E. coli 
expression vector pProEX-HTb to generate pProEX-HTb-CRAb-FM27. Positive clones were 
confirmed by colony PCR. Figure 3.1 shows colony PCR products of three E. coli transformants, 
each containing the amplified DNA band of the expected size (932bp). Further confirmation 
was achieved by RE digestion (not shown). 
3.3.1.2 E. coli expression analysis 
Expression of CRAb-FM27 in E. coli was carried out and induced cultures of the pProEX-HTb-
CRAb-FM27 were sampled every hour for three hours. The samples were analysed by anti-his 
western blot to determine initial expression, and at which time after induction the highest 
levels of expression were visualised. Figure 3.2 shows a western blot of scFv protein 
expression up to three hours after induction. Bands of the expected size (approximately 
Figure 3.1. 1% agarose gel displaying colony PCR products confirming pProEX-HTb-CRAb-FM27 transformation into E. coli.   
 
1Kb ladder (1Kb DNA ladder), CRAb-FM27 (PCR products of three E. coli colonies with DNA fragments confirming CRAb-
FM27 gene ligation into pProEX-HTb seen as 932bp fragments). 
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35KDa) were seen as indicated by the arrow in Figure 3.2. The highest level of expression was 
observed 2 hours after induction as visualised by the darkest band. A histidine marker was 
used as a positive control and a crude preparation of E. coli hosting pProEX-HTb only was used 
as the negative control, which showed no non-specific binding (background) of the primary 
antibody. 
3.3.1.3 Purification of E. coli-produced CRAb-FM27 
Purification of the CRAb-FM27 scFv produced in E. coli was done using the batch binding 
method. The binding and wash buffers contained no imidazole but the elution buffers ranged 
from 10mM-500mM imidazole to determine at which concentration the protein would be 
eluted. The fractions collected during purification were analysed on an anti-his western blot 
and Coomassie stained gel (Figure 3.3 A & B respectively). The western blot shows some scFv 
present in the flow through (FT) and none detected in the two wash fractions (W1&W2). The 
elution fractions (E1-E4) show that most of the protein was eluted at 0.01M imidazole (E1) as 
it gave the darkest band on the western blot. The subsequent elutions (E2-E4) contained less 
of the scFv, with a steep reduction in band intensity observed between them.  The Coomassie 
gel (Figure 3.3 B) shows a reduction of contaminating proteins from the crude sample and 
enrichment in fractions of the scFv. The flow through and wash fractions show the presence 
Figure 3.2. Western blot displaying hourly small scale time trial of E. coli expressed scFv.  
Marker (PageRuler™), His-marker (histidine ladder, positive control), E. coli-expressed CRAb-FM27 shown over hours (h) 1, 
2 & 3 post-induction. Negative control (crude extract of E. coli containing an empty pProEX-HTb vector). Black arrow 
indicating position of scFv at 35KDa. Anti-his 1/2000. 
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of other proteins as seen by the bands in the Coomassie. The reduction of band intensity 
between the FT and wash fractions indicates successful removal of unbound native E. coli 
proteins. The elution fractions in the Coomassie-stained gel show the presence of possible 
native E. coli proteins (red arrow) that co-eluted with the scFv (black arrow), shown in lane 
E1.   Quantification of the protein was carried out by Bradford assay, as using gel densitometry 
was not possible (not shown). This yielded 0.104µg/µl, for a final yield of 520µg.  
3.3.2 N. BENTHAMIANA-EXPRESSION AND PURIFICATION OF CRAB-FM27 SCFV. 
3.3.2.1 Cloning of CRAb-FM27 into plant expression vectors and construct confirmation 
The CRAb-FM27 gene was successfully digested from the pUC57 vector and ligated into the 
pTRAKc-ERH plant expression vector. Subcloning using different RE sites allowed for the 
generation of two variations of the same construct; pTRAKc-ERH-CRAb-FM27 and pTRAKc-A-
CRAb-FM27. Positive clones were confirmed by colony PCR. This was carried out on four 
colonies per construct and products run on a 1% agarose gel (Figure 3.4). The pTRAKc-ERH-
CRAb-FM27 showed all four colonies contained the construct as a 1041 bp product was seen 
Figure 3.3. Batch binding purification of E. coli-expressed CRAb-FM27 fraction analysis.   
(A) Anti-his 1/2000 western blot and (B) Coomassie stained SDS-PAGE. Marker (Color Prestained protein standard), crude 
(5ul cell culture pre-purification), FT (Flow Through), W1 (Wash 1), W2 (Wash2), E1 (Elution 1, Imidazole 0.01M), E2 (Elution 
2, Imidazole 0.1M), E3 (Elution 3, Imidazole 0.25M), E4 (Elution 4, Imidazole 0.5M). Black arrows indicating CRAb-FM27 at 
≈35KDa and red arrow indicating contaminating protein. 
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in each lane. However, only 2 of the four colonies showed positive 1023 bp PCR products for 
the pTRAKc-A-CRAb-FM27 construct. 
3.3.2.2 Small-scale plant expression of CRAb-FM27 
Initially the two constructs (pTRAKc-ERH-CRAb-FM27 and pTRAKc-A-CRAb-FM27) were 
syringe-infiltrated into three plants each at bacterial OD600 values of 0.5 and 1.0. Crude leaf 
extracts were screened after 1, 3 and 5 days post infiltration (dpi) and analysed for 
recombinant scFv expression by anti-his western blot. This was done to determine the optimal 
day of harvest as well as the optimal bacterial OD600 to use for large scale expression (Figure 
3.5). The positive control used was the crude sample of E. coli-expressed CRAb-FM27 and the 
negative control was extracted crude leaf sample infiltrated with A. tumefaciens hosting 
pTRAKc-ERH only. Total protein for each sample was measured by Bradford assay, for equal 
amounts to be loaded into each lane. This gives a more reliable and accurate comparison 
between the differences seen in expression of the two variations of recombinant constructs.  
Crude extracts from leaves infiltrated with pTRAKc-ERH-CRAb-FM27 (Figure 3.5 A) showed 
the highest expression level of scFv on day 3 after infiltration at an OD600 of 1.0, as the band 
in this lane is darker than those seen on day 1 (which barely showed any expression) and day 
5 (which is very similar to day 3). However, crude extracts from leaves infiltrated with the 
Figure 3.4. 1% agarose gel displaying Agrobacterium colony PCR confirming plant vectors with CRAb-FM27 gene insert. 
1Kb ladder (DNA ladder), pTRAKc-ERH-CRAb-FM27 (1041bp) and pTRAKc-A-CRAb-FM27 (1023bp) indicating four colonies 
per construct and DNA fragments indicating successful construct transformation into Agrobacterium. 
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pTRAKc-A-CRAb-FM27 construct showed the highest expression on day 5 after infiltration 
with a culture OD600 of 1.0 (Figure 3.5 B). Additional faint bands of a lower molecular weight 
(≈15KDa) were seen in the leaf extracts from the pTRAKc-A-CRAb-FM27 constructs (Figure 3.5 
B), indicated by the blue arrow. These were repeatedly observed for three biological 
experiments when infiltrated with pTRAKc-A-CRAb-FM27 but not observed in samples 
infiltrated with pTRAKc-ERH-CRAb-FM27.  
In order to further confirm successful expression in plants of the CRAb-FM27 scFv the same 
samples were run on a western blot for each construct as before. The blot was then probed 
using an anti-chicken alkaline phosphatase conjugate antibody for the direct detection of the 
scFv (not shown). The same protein bands of the same molecular weight (≈35KDa) as in Figure 
3.5 were observed. This showed that the specific chicken scFv was being expressed as it could 
be detected using an anti-chicken antibody. 
Figure 3.5. Western blot displaying small scale time trial of N. benthamiana-expressed CRAb-FM27 scFv. 
(A) pTRAKc-ERH-CRAb-FM27 and (B) pTRAKc-A-CRAb-FM27 constructs sampled. Negative control (crude leaf extract
infiltrated with empty pTRAKc vector), Positive control (Crude E. coli-expressed CRAb-FM27), Marker (Color Prestained
protein standard). Days 1, 3 and 5 post infiltration, each with an OD600 of 0.5 and 1 tested. 50µg of total soluble protein
loaded into each lane. Black arrow indicating position of CRAb-FM27 scFv (≈35KDa) and blue arrow indicating possible
degraded scFv (15KDa). Anti-his 1/2000.
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3.3.2.3 Apoplast extract comparison between constructs 
Apoplast extraction was carried out to determine if extraction using this method would be 
more effective than homogenising whole leaves. There is substantially less protein within the 
apoplastic space in comparison to within the cells and so it was thought that secretion of 
recombinant proteins into this space would consist of less contaminating proteins within the 
sample extracts. This would reduce the need for extensive purification and hence simplify 
recombinant protein extraction.   
Three plants were vacuum infiltrated with pTRAKc-ERH-CRAb-FM27 and another three with 
pTRAKc-A-CRAb-FM27 at an OD600 of 1.0. Three days post infiltration the same weight of leaf 
material from each plant and for each construct was subjected to apoplast extraction. The 
samples were analysed by an anti-his western blot and a comparison of all three biological 
repeats (B1, B2 and B3) was done between both constructs (Figure 3.6). The results showed 
successful extraction of the scFv from the apoplast in all samples (Figure 3.6, black arrow), 
with the majority seen from the pTRAKc-A-CRAb-FM27 extract as expected when compared 
to that of the pTRAKc-ERH-CRAb-FM27 extract.  This blot also showed that the scFv extracted 
from the pTRAKc-A-CRAb-FM27 construct alone, had a lower molecular weight band of 
Figure 3.6. Western blot displaying N. benthamiana leaf apoplastic extracts containing CRAb-FM27.  
Negative control (crude leaf extract infiltrated with empty pTRAKc vector), Positive control (crude E. coli expressed 
CRAb-FM27), Marker (Color Prestained protein standard), Biological repeats (B1, B2 and B3) of apoplastic extracts taken 
on day 3 post infiltration at OD600 1.0 of both constructs. Black arrow indicating position of CRAb-FM27 scFv (≈35KDa) 
and blue arrow indicating possible degraded scFv (15KDa). Anti-his 1/2000. 
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approximately 15KDa (Figure 3.6), indicated by the blue arrows, and as seen before in Figure 
3.5 B.  
3.3.2.4 Large-scale affinity purification of recombinant plant-produced scFv 
The pTRAKc-ERH-CRAb-FM27 construct was chosen to continue purification with, as it 
showed the highest yields of protein the soonest after infiltration and also showed no signs 
of degradation, i.e. the lower molecular weight bands visualised from samples infiltrated with 
pTRAKc-A-CRAb-FM27 (Figure 3.5). To achieve a suitable working volume for purification 
using IMAC (nickel resin) and the ÄKTA FPLC system, a large-scale infiltration was done. The 
pTRAKc-ERH-CRAb-FM27 construct was vacuum infiltrated into 12 plants, using the optimal 
parameters established for the small-scale expression (see section 3.3.2.2.). The 
homogenised plant extract was then purified using the ÄKTA system.  The flowthrough, wash 
and elution fractions are shown in a chromatogram depicting protein absorbance readings at 
280nm (Figure 3.7). The flowthrough region early on in the chromatogram shows a large 
absorbance peak spanning the fractions (1-15). This peak is thought to contain mostly the 
native plant proteins which have not bound to the resin during the loading of the plants 
extract onto the column. This initial peak decreases rapidly during the wash phase (fractions 
16-20). The elution phase consisted of an increasing imidazole concentration gradient across 
fractions 21-40 and then an increase to 0.5M imidazole across fractions 41-46 (Figure 3.7, 
green line as a percentage of 0.5M imidazole). A second peak (increase in protein absorbance) 
is seen from fraction 23 to fraction 25. A third peak of absorbance across fractions 27-28 is 
also seen. Subsequent to the third peak, the absorbance at 280nm gradually increases across 
fractions 31-42 which then peaks again and plateaus (43-46). The absorbance seen across 
these fractions seems to follow the increase of imidazole being added. It is thought to be the 
impurities within the imidazole, which tend to absorb light at 280nm, as it was not of a pure 




The fractions from the ÄKTA purification were analysed by an anti-his western blot and 
Coomassie staining, in order to confirm which of the protein peaks contained the CRAb-FM27 
protein (Figure 3.8 A & B respectively). The flow through (FT) fractions 5-7 contained in the 
first large absorbance peak, contained very little scFv as only a faint band was seen on the 
western blot.  The Coomassie-stained gel showed many protein bands and a smear of protein 
in the FT 5-7 sample, suggesting that the high absorbance in these fractions largely consists 
of contaminating plant proteins. The wash fractions (W 17-19) in the western blot show no 
scFv protein bands indicating that it was successfully bound to the column. There were no 
protein bands seen in the W17-19 samples on the Coomassie gel either (Figure 3.8 B). Eluted 
fractions E23-E25 across the second protein peak showed the presence of scFv as visualised 
by a ≈35kDa band. However, the Coomassie-stained gel of the same fractions showed a range 
Figure 3.7. Chromatogram trace of ÄKTA purification of N. benthamiana-produced CRAb-FM27.  
The X axis indicating fractions of the Flow through (1-15), Wash (16-20) and Elution (21-46). Y axis showing % of elution 
buffer. Blue line indicating absorbance at 280nm, green line showing increasing gradient as a percentage of elution buffer 
containing 0.5M Imidazole. Black box indicating were best purity and quantity of scFv was found. 
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of other proteins bands of different sizes and very little scFv. However, the eluted fractions 
from the third peak across E27 and E28 showed successful enrichment of the scFv (Figure 3.7, 
black box) as seen by the darkest band on the western blot and a single protein band on the 
Coomassie-stained gel with little contaminating proteins observed. No protein bands were 
visualised in fractions E40-42 indicating that all the scFv was eluted.  There were no protein 
bands in these fractions on the Coomassie-stained gel either, suggesting that the peak 
visualised on the chromatogram may have been due to absorbance of impurities in the 
imidazole. Quantification of fraction E27-28 was done by SDS gel densitometry using 
Coomassie staining and a BSA standard curve (not shown). This yielded 0.098µg/µl of the scFv 
which was eluted and pooled to give a total of 10ml and therefore giving a total of 980µg of 
scFv.    
    
 
Figure 3.8. Analysis of ÄKTA fractions for purification of N. benthamiana-produced CRAb-FM27 scFv.  
(A) Western blot Anti-his 1/2000 and (B) SDS-PAGE Coomassie stained. Marker (Color Prestained protein standard), Crude 
(pre-purification crude leaf extract), Flow Through fractions (FT 5-7), Wash fractions (W 17-19), Elution fractions (E 22-42). 
Black arrows showing position of CRAb-FM27 scFv (≈35KDa). 
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3.3.3 GLYCO-PROFILING OF PLANT PRODUCED CRAB-FM27 
A lyophilised sample of purified plant made scFv was analysed for N-glycosylation.  Results 
are shown as a percentage of the different glycoforms in Table 3.1. The predominant 
glycoforms are Man8, Man9 and MMXF and GnGnXF3 which show to make up over 75% of 
the glycoforms within the scFv protein.  The other glycoforms screened for included Man5, 
Man6, Man9+Hex, MMX, MUX, Man4XF3, Man4X, GnGnF, AGnF6, AAF6, GnM, GnGn and AA, 
which were not present. 
Table 3.1. The relative proportion of the different glycoforms are depicted as a percentage. 










The CRAb-FM27 scFv was identified by Foord et al. (2007) and cloned and expressed in E. coli 
to be used as a competing reagent in a C-ELISA, and was successful in differentiating between 
FMDV-infected and -vaccinated animal serum. This work describes the expression of the scFv 
in N. benthamiana, as expression of recombinant proteins in a plant system is potentially a 
cheaper method of production. It was decided that expression of the scFv in an E. coli system 
would be conducted in parallel to show reproducibility of expression and to generate positive 
control proteins to verify the plant expression work.  
The small-scale expression of the scFv in plants was used for optimisation of parameters (time 
of harvest and culture OD600) to be used for large scale production. Two variations of 
recombinant pTRAKc vectors expressing the scFv were tested to determine whether targeting 
to different subcellular organelles would influence the level of protein expression.  The first 
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was termed pTRAKc-ERH-CRAb-FM27, which had a SEKDEL signal to retain the scFv in the 
endoplasmic reticulum (ER) (Denecke, De Rycke and Botterman, 1992). Retention of 
recombinant proteins within the ER is thought to protect proteins by shielding them from 
proteases found within the cytoplasm, and therefore help increase yields (Pillay et al., 2013). 
The second variant was the pTRAKc-A-CRAb-FM27 construct which lacks the SEKDEL signal, 
therefore allowing the scFv to move through the secretory pathway into the apoplastic space. 
Previous work has shown that targeting and extracting proteins from the apoplastic space 
yields higher levels of more pure scFvs (Fischer et al., 1999). This is due to the limited amount 
of native plant proteins present in the apoplast compared to within the cell.  
The optimisation time trials were used to determine optimal OD600 for infiltration and time of 
harvest for both the pTRAKc-ERH-CRAb-FM27 and pTRAKc-A-CRAb-FM27 constructs, using 
leaf clippings (Figures 3.5 A &B). The results showed that both constructs yielded successful 
expression of the scFv. However, the pTRAKc-ERH-CRAb-FM27 vector showed higher levels of 
expression earlier (at 3 dpi) compared to pTRAKc-A-CRAb-FM27 (at 5 dpi). The pTRAKc-A-
CRAb-FM27 samples showed expression of the scFv as a ≈35KDa protein band but a smaller-
sized band of approximately 15KDa (Figure 3.5 B, blue arrow) was also visualised. This lower 
molecular weight band could be degradation of the scFv due to the lack of ER retention and 
therefore exposure to plant proteases (Pillay et al, 2013).  
The molecular weight of CRAb-FM27 protein is not disclosed in the Foord et al. (2007) paper, 
but the theoretical size calculated in silico using the ExPASy server tool (Gasteiger et al., 2005) 
was calculated to be 27.5KDa. However, this work shows that the successfully expressed scFv 
in E. coli and N. benthamiana was approximately 35KDa in size (Figure 3.2 and Figure 3.5 
respectively). It is possible that this perceived increase in molecular weight may be due to 
post-translationally modified amino acids.  Post-translational modification of proteins (e.g. N-
glycosylation) has been known to increase the apparent molecular weight (MW) of a protein 
on a SDS-PAGE (gel-shift) (Lu et al., 1997; Selcuk Unal et al., 2008).  
N-glycosylation is one of the major post-translational modifications in eukaryotic systems and 
is largely similar between mammals and plants. The initial processing of proteins in all 
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eukaryotes, starts in the ER and mainly consists of the oligo-mannosidic N-glycans; 
Glc3Man7GlcNAc2 (Man7), Glc3Man8GlcNAc2 (Man8) and Glc3Man9GlcNAc2 (Man9). In plants, 
the Man8 glycoform is usually moved down the secretory pathway, through the cis, medial 
and trans-Golgi compartments to form complex N-glycans (e.g. GnGnXF3). The GnGnXF3 
glycoform is then sorted into either the vacuole or apoplast for further processing into the 
MMXF3 complex N-glycan (Bosch et al., 2013). Glycosylation is a complex process and consists 
of many precursor glycan forms and therefore, to determine the extent of N-glycosylation, 
the plant purified CRAb-FM27 protein was analysed for its N-glycan profile. The Man7, Man8 
and Man9 glycoforms made up around 44% of the total N-glycosylation, which was to be 
expected as the protein was targeted and retained within the ER. The majority of the other 
glycoforms detected consisted of the complex GnGnXF3 and MMXF3 N-glycans, which again 
made up around 44% of the total glycosylation. This was an unexpected result as these 
glycoforms are usually processed in the Golgi and vacuole/apoplast, which the scFv should 
not have been exposed to. This is due to the scFv containing the SEKDEL signal for retention 
in the ER. However, incomplete ER retention of recombinant proteins possessing a SEKDEL 
signal has been identified as a common trait for recombinantly expressed proteins in seeds 
(Arcalis et al., 2004; Petruccelli et al., 2006; He et al., 2012). Even though the extracts analysed 
were from the leaves and not from the seeds, these findings might suggest that the retention 
in the ER of the recombinant scFv using the SEKDEL signal, might not be entirely efficient. 
With the scFv consisting of complex N-glycoforms (Table 3.1) it could explain why the scFv is 
seen as a band having a higher molecular weight on the western blot (≈35KDa) than at the 
calculated 27.5KDa. There is also a slight difference in size between the E. coli-produced 
CRAb-FM27 (slightly lower MW) and the N. benthamiana-produced CRAb-FM27 (slightly 
higher MW) (Figure 3.5). This difference, estimated to be about 2-3KDa, could be due to the 
extensive N-glycosylation, or possibly the high levels of acetylation that take place in plants 
which is not seen to the same extent in bacteria (Dell et al., 2010). However, the latter 
possibility was not tested. Moreover, when the scFv protein sequence was run through an in-
silico prediction server for N-Glycosylation sites (Gupta, Jung and Brunak, 2004) no 
glycosylation sites were identified.  
In order to further confirm that the plant and E. coli-produced CRAb-FM27 protein was 
derived from a chicken antibody, a western blot with CRAb-FM27 protein was probed with an 
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anti-chicken IgY alkaline phosphatase conjugate antibody (not shown). The western blot 
showed the same sized band (≈35KDa) as observed with the anti-his blot (not shown), 
indicating that the recombinant scFv was folded correctly for binding of the secondary 
antibody. This also confirmed that the anti-chicken conjugate antibody could be used in future 
work to prove the functionality of the scFv in ELISAs and western blots (Chapter 4). 
The distribution of recombinant CRAb-FM27 in the apoplast was surveyed in extracts from 
leaves infiltrated with pTRAKc-ERH-CRAb-FM27 and pTRAKc-A-CRAb-FM27 and harvested at 
3 dpi.  It was expected that the pTRAKc-A-CRAb-FM27 (lacking the SEKDEL ER retention signal) 
would direct the recombinant protein into the apoplast and that the pTRAKc-ERH-CRAb-FM27 
(having the ER retention signal) would result in the retention of the recombinant protein in 
the ER. When infiltrated plant leaves were subjected to an apoplast extract protocol, a faint 
band was detected indicating low levels of scFv from the pTRAKc-ERH-CRAb-FM27 expression 
(Figure 3.6).  One would have expected no band, but it is possible that the apoplast extraction 
method may have caused some physical damage to the leaves resulting in ‘leakage’ of the 
recombinant protein into the preparation. It has also been hypothesised that the retention of 
the scFv within the ER is not completely efficient, allowing for secretion into the apoplastic 
space, as the N-glycoforms detected in the scFv shows processing of the protein in the Golgi 
and apoplast (as explained above).  Higher levels of the scFv from the pTRAKc-A-CRAb-FM27 
construct were observed, which was expected.  However, there appears to be an increase in 
the presence of degraded proteins, as seen by the lower band (Figure 3.6, blue arrow). This 
could possibly be due to proteolysis caused by the abundant levels of proteases in the 
apoplast. The advantage of using an apoplastic extract is the low abundance of native plant 
proteins present compared to a homogenised extract, reducing the need for complex 
purification. This low abundance of proteins in the apoplastic fluid compared to the whole 
leaf homogenate was observed and confirmed when running the samples on a Coomassie 
(not shown). However, an increase in recombinant scFv proteolysis, possibly resulting from 
the known high abundance of proteases within the apoplast (Delannoy et al., 2008; Pillay et 




The pTRAKc-ERH-CRAb-FM27 construct was therefore selected for further experimentation 
as infiltration resulted in greater levels of recombinant protein being produced earlier, and 
retention of the scFv within the ER appeared to limit degradation of the protein. With the 
optimised conditions for scFv expression in both N. benthamiana and E. coli having been 
established, a large-scale expression for both was done in order to optimise purification. 
Purification of E. coli made scFv was successful using the batch binding method.  The scFv was 
eluted at a very low imidazole concentration (0.01M) which suggested that the binding buffer 
should not contain imidazole during purification of plant produced scFv, when using the ÄKTA 
system. The lack of imidazole in the binding buffer resulted in increased non-specific binding 
of proteins to the resin but would reduce the risk of losing the scFv in the flow through and 
wash fractions. In order to limit co-elution of contaminating native plant proteins, a shallow 
imidazole gradient was used to better separate the scFv and obtain a more pure fraction. The 
plant-produced scFv was successfully eluted with the majority of the protein collecting in 
fractions E27-28 and containing very few contaminating proteins (Figure 3.8). 
The purified samples of CRAb-FM27 from both E. coli (batch binding) and from N. 
benthamiana (ÄKTA) were then quantified. N. benthamiana production gave a range between 
0.047µg/µl and 0.098µg/µl, with a best recovery of 85% of the total scFv from the crude 
extract, after purification. Quantification of the E. coli expressed scFv could not be achieved 
using gel densitometry, as the concentration of the protein was too low to be seen on a 
Coomassie-stained gel. A western blot could not be used for densitometry as the E. coli 
expressed scFv had two 6xhis tags, whereas the standard would only have one and so would 
not be comparable.  Therefore, the E. coli-expressed scFv was quantified using a Bradford 
assay. The concentration of the protein ranged from 0.094µg/µl to 0.104µg/µl; however, this 
was the total protein concentration which included some contaminating proteins.  
The CRAb-FM27 scFv was successfully expressed and purified from both E. coli and N. 
benthamiana systems and its functionality was tested in an ELISA (Chapter 4), to see if they 





TESTING THE FUNCTIONALITY OF N. BENTHAMIANA AND E. COLI PRODUCED REAGENTS  
4.1 INTRODUCTION 
A competitive-ELISA (C-ELISA) in the field of FMDV diagnostics could reduce the cost of 
testing, as the reagents required for testing will not be confined to just one species of animal 
sera being investigated. This is because the antigen is coated into the wells of the ELISA plate, 
and animal serum to be analysed for infection is added, along with the competing antibody. 
The detection of the bound competing antibody to the antigen is done using a secondary 
antibody, which will determine the infection status of the animal. Therefore, a secondary 
antibody to detect specific antibodies of the animal under investigation is not needed. In the 
context of the Kruger National Park (KNP) in South Africa and the surrounding buffer and 
FMDV surveillance areas, this is important when screening animals in these regions. The 
reason for this is that livestock, which is translocated to and from the zones of the KNP, 
consists of other animal species as well as cattle.  
The desired reagents for an FMDV C-ELISA would consist of a NSP with which to coat the wells 
of the plate, and an antibody to compete with antibodies in the animal serum for the binding 
of the antigen. In Chapter 2, I showed that of the candidates expressed in N. benthamiana, 
the FMDV-NSP 3B-O was the most favourable to use as a coating antigen as high levels could 
be expressed in plants and successfully purified. The same 3B-O protein was also successfully 
expressed and purified using an E. coli expression system, to be used for comparative 
functionality testing. In Chapter 3 it was shown that the CRAb-FM27 scFv could be successfully 
expressed and purified from both N. benthamiana and E. coli.   Thus, it was decided to use 
this as the competing antibody in a C-ELISA together with the plant and E. coli-produced 
coating antigen 3B-O.  E. coli-expressed CRAb-FM27 scFv was tested for comparative 
functionality.  
It is vital that the CRAb-FM27 scFv is able to bind the 3B-O antigen.  To determine which of 
the systems produced functional proteins, combinations of E. coli and plant produced antigen 
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and scFv were tested together. The combinations tested, were to determine if the scFv could 
bind the antigen and were as follows: plant-produced scFv tested against plant and E. coli-
produced 3B-O antigen, and E. coli-produced scFv tested against plant and E. coli-produced 
3B-O antigen. The initial testing of the scFv was done via western blotting, and then 
subsequently by an I-ELISA, to show functionality and binding capability to the antigen in this 
format. 
It is also imperative that antibodies in infected but not in vaccinated animal serum can bind 
and recognise the 3B-O antigen. Therefore, the recombinant N. benthamiana and E. coli-
produced 3B-O antigen was initially tested in an I-ELISA, with infected animal serum to show 
whether it could demonstrate its ability to differentiate between serum from infected and 
vaccinated animals. Having established this, both the recombinant 3B-O antigen and CRAb-
FM27 scFv proteins were used in combination in a C-ELISA to identify their potential as 
functional diagnostic reagents in this format.  
4.2 MATERIALS AND METHODS. 
4.2.1 FUNCTIONALITY TESTING OF CRAB-FM27 ON A WESTERN BLOT.  
Plant-produced and E. coli-produced CRAb-FM27 antibodies were tested for their ability to 
bind to plant-produced or E. coli-produced 3B-O. The 3B-O antigen purified from both plant 
and E. coli expression systems (approximately 300ng) were run on separate SDS 
polyacrylamide gels and blotted onto nitrocellulose. Purified plant and E. coli-produced CRAb-
FM27 scFvs were diluted (1:3, approximately 300µg) in blocking buffer and used to separately 
probe both plant-produced and E. coli-produced 3B-O blots. Alkaline phosphatase-conjugated 
anti-chicken antibody was used as the secondary antibody (Anti-chicken IgY (IgG) (whole 
molecule)-Alkaline Phosphatase, Sigma-Aldrich) in a 1:5000 dilution. The procedure was 





4.2.2 FUNCTIONALITY OF RECOMBINANT CRAB-FM27 IN INDIRECT-ELISA (I-ELISA).  
The combination for testing the binding of the scFv to the antigen in an I-ELISA was similar to 
that described in section 4.2.1.  Purified plant-produced 3B-O and E. coli-produced 3B-O (100 
μl undiluted, 1:2 and 1:10 diluted in coating buffer (1XPBS, pH7.4)) were used to coat the 
wells of separate 96-well Maxisorp™ microtitre plates (Nunc-Immuno™, Sigma-Aldrich). The 
controls included coating buffer only and 1:100 dilutions of either E. coli or plant negative 
crude extract (extracted from E. coli transformed with empty pProEX-HTb vector or from 
plants infiltrated with Agrobacterium transformed with empty pRIC3.0-HT vector, as negative 
controls) for background normalisation. The E. coli and plant-produced scFv was diluted (1:3) 
and coated in three of the wells per plate that were to be probed using the same scFv. This 
was a maximum absorbance control to confirm detectability of the scFv using the secondary 
antibody (positive control). The plates were incubated overnight at 4oC with shaking. The 
plates were blocked with blocking buffer (5% non-fat dry milk in 1XPBS) using 200µl per well 
and incubated at 37oC for 1 hour with shaking. Wells were rinsed with 200µl of 1XPBS before 
the recombinant purified scFv expressed in E. coli or N. benthamiana was added. The scFv 
was diluted in blocking buffer at a 1:3 dilution and 100µl added per well. The plates were 
incubated at 37oC for 1 hour and again rinsed with 1XPBS. The plates were washed (1XPBS, 
0.05% tween 20 - PBST) three times with 200µl. The anti-chicken alkaline phosphatase 
conjugated IgY (Sigma-Aldrich) was added to each well at a 1:5000 dilution in blocking buffer 
at 100µl per well. The plate was incubated at 37oC for 1 hour and then washed four times in 
PBST. After washing, 200μL SIGMAFAST™ p-Nitrophenyl phosphate substrate (pNPP, Sigma) 
was added per well and plates incubated in the dark for 30 minutes. The absorbance was 
detected at 405 nm on a BIO-TEK® Powerwave XS microtitre plate reader. This experiment 
was carried out in quadruplicate.  
4.2.3 FUNCTIONALITY OF RECOMBINANT 3B-O ANTIGEN USING I-ELISA TO DETECT ANTI-FMDV ANTIBODIES IN 
ANIMAL SERUM.  
The same methodology was followed as described in section 4.2.2, with the following 
changes. 107ng of 3B-O antigen from E. coli and N. benthamiana was separately coated across 
a 96-well plate. Either E. coli or leaf crude extract from an empty vector (negative control, 
107ng total protein coated) was used for background normalisation. E. coli expressed and 
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purified 3AB1 protein obtained from collaborators at INTA (Buenos Aires, Argentina), which 
has previously been shown to detect infected animal serum, was used as a positive control. 
The same amount of 3AB1 protein was diluted in coating buffer and added to the wells to be 
used as a positive control. Each row of wells on the plate was coated with the test antigen 
(3B-O from E. coli or N. benthamiana), a background control (E. coli or plant negative), and a 
positive control (3AB1). All serum samples tested but one were from guinea pigs which had 
previously been infected with guinea pig-adapted FMDV; the remaining serum sample was 
from a vaccinated guinea pig (FMDV-inactivated virus, serotype C85) (Table 4.1). Serum 
samples were taken 15-20 days post-infection or vaccination. These serum samples were 
diluted to 1:10 with blocking buffer and 100µl added per well. Each serum sample was added 
to a separate row of wells. Anti-Guinea pig alkaline phosphatase-conjugated (Anti-Guinea Pig 
IgG (whole molecule) −Alkaline Phosphatase, Sigma-Aldrich) secondary antibody was used at 
1:5000. The absorbance readings were read at 405nm and experiments were performed in 
quadruplicate.   
Table 4.1. FMDV-serum from infected and vaccinated Guinea pig of different serotypes and subtypes. 
Serotype Subtype Status 
C C85 Infected 
C CC59 Infected 
A A24 Infected 
A A87 Infected 
O O1 Infected 
O O1C Infected 
C C85 Vaccinated 
 
4.2.4 COMPETITIVE-ELISA TO TEST FUNCTIONALITY OF RECOMBINANT ANTIGEN AND SCFV IN THE PRESENCE OF 
FMDV ANTI-SERUM.  
The E. coli and N. benthamiana-produced 3B-O antigen and the N. benthamiana-produced 
scFv were tested together to determine if they could differentiate infected from vaccinated 
Guinea pig serum in a competitive-ELISA. The E. coli and N. benthamiana-produced 3B-O 
antigen was diluted (107ng) in coating buffer and coated in separate 96-well Maxisorp™ 
microtitre plate overnight at 4oC. The background control included either E. coli or leaf 
material (extracted from an empty vector, negative; 107ng total protein) for background 
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normalisation. The plate was blocked as previously described and the serum from FMDV-
infected Guinea pigs added at a range of dilutions (1:10, 1:100, 1:1000 and 1:10 000). This 
was incubated at 37oC for 1 hour and thereafter, without discarding the diluted serum, the 
plant-produced scFv diluted to 1:3 in coating buffer (1XPBS, pH7.4) was added. The maximum 
absorbance control included the addition of the scFv to the antigen coated well, in the 
absence of the animal serum. This would give the maximum absorbance and therefore the 
binding of the scFv to the antigen without the competition of the serum.  The plate was re- 
incubated at 37oC for 1 hour, followed by three wash steps as before. The anti-chicken alkaline 
phosphatase-conjugated secondary antibody (diluted at 1:5000) was added and incubated for 
1 hour at 37oC. The plate was washed four times and the pNPP substrate added and incubated 
as described previously. The absorbance was read at 405nm and experiments performed in 
triplicate. 
4.3 RESULTS 
4.3.1 FUNCTIONALITY OF RECOMBINANT CRAB-FM27 SCFV ON A WESTERN BLOT.  
Having previously described the successful expression and purification of both the 3B-O 
antigen and CRAb-FM27 scFv in N. benthamiana and E. coli, the functionality of the 
recombinant CRAb-FM27 was tested for its ability to bind to recombinant 3B-O in a western 
blot. The 3B-O antigen produced in N. benthamiana and E. coli were separately probed with 
either the N. benthamiana or E. coli-expressed scFv. In all the western blots tested, a positive 
control blot was run with the same samples but probed using the anti-his antibody, which 
was used to confirm the presence of the antigen. The negative control was either crude N. 
benthamiana leaf extract infiltrated with Agrobacterium containing an empty pRIC3.0-HT 
vector or crude E. coli extract transformed with empty pProEX-HTb vector, depending on the 
system the antigen was being expressed in.  
The 3B-O E. coli produced antigen was successfully detected as a 13 KDa sized protein with 
the N. benthamiana-produced scFv (Figure 4.1 A, black arrow). The positive control western 
blot (Figure 4.1 B) showed the same 13KDa band when probing with the anti-his primary 
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antibody.  However, in addition a second ≈20 KDa size protein band was seen (Figure 4.1 B, 
blue arrow). In both blots the negative controls showed no protein bands.  
The N. benthamiana expressed 3B-O antigen was also run on a western blot and probed in 
the same way as the E. coli produced 3B-O. The N. benthamiana-expressed scFv only showed 
detection of the N. benthamiana-expressed 3B-O protein as extremely faint bands at the 
lower (13KDa) position (data not shown). Whereas, the anti-his probed blot again showed the 
upper and lower bands as previously seen for the 3B-O antigen.  
  
Western blots with N. benthamiana or E. coli-produced 3B-O were probed with the E. coli-
produced scFv; however, these showed no protein bands in either blot (data not shown).  
However, the positive anti-his blots again showed the upper and lower bands as seen before 
in Figure 4.1 B, indicating that the 3B-O antigen was present. 
 
Figure 4.1. Western blot to detect 3B-O antigen using plant made scFv.  
(A) Probed with purified plant scFv (1:3 dilution) as primary antibody and conjugate anti-chicken as secondary antibody 
(1:2000). (B) Probed with anti-his antibody (1:2000) and conjugate anti-mouse secondary antibody (1:10 000). Marker 
(Color Prestained protein standard), 3B-O (E. coli-produced antigen), negative control (crude E. coli extract containing 




4.3.2 FUNCTIONALITY OF RECOMBINANT CRAB-FM27 IN I-ELISA  
The detection of the E. coli-produced 3B-O by the N. benthamiana-expressed scFv was 
successful and was clearly demonstrated in a western blot (Figure 4.1). Detection of N. 
benthamiana-expressed 3B-O using the same scFv was not definitive as the bands seen on a 
western blot were extremely faint. The lack of detection of the 3B-O from both expression 
systems using the E. coli-expressed scFv on a western blot could be a result of the lack of 
sensitivity of the assay. The requirement of the 3B-O antigen to present conformationally 
appropriate epitopes for scFv binding, might be the reason for the limited detection observed. 
Therefore, an I-ELISA was performed using these samples as it is a more sensitive assay which 
allows for conformational dependence. 
The 3B-O antigen produced from both E. coli and N. benthamiana was coated onto the wells 
of an ELISA plate at varying dilutions. It was assumed that due to there being a low 
concentration of antigen in the samples, that an undiluted, 1/2 dilution and a 1/10 dilution 
would allow for a better range for a signal to be observed. The scFv was added and allowed 
to bind before addition of the secondary anti-chicken conjugate. These readings were then 
compared to a background control, of either crude leaf extract or crude E. coli extract from 
empty vector samples, probed for by the scFv in the same way. It was though that due to the 
3B-O antigen being partially purified and therefore, having a very low concentration of native 
plant or E. coli proteins in the sample, it was decided that a 1/100 dilution of crude negative 
extract was to be used as a background control as it might consist of native proteins at a 
similar concentration of that of the partially purified antigen. It was also thought that a high 
concentration of negative crude plant or E. coli extract would give too much background 
binding, and therefore could interfere with the absorbance reading. The scFv was coated alone 
in the well as a maximum absorbance control or as a positive control to show that the secondary 
antibody was detecting the scFv. This control would give a maximum absorbance in the assay and 
therefore, no other signal should exceed this and if so could be considered an outlier. The 
combinations of 3B-O antigen and scFv to be tested are the same as mentioned in the western 




The first panel (Figure 4.2 A) shows the N. benthamiana-produced 3B-O antigen coated at 
different dilutions, and probed for using the N. benthamiana-produced scFv. The readings of 
the diluted 3B-O samples detected by the scFv were compared to the plant background 
control (1:100 crude leaf extract). A significant difference was only observed in the 1:2 dilution 
of the antigen, signifying that the undiluted and the 1:10 dilution samples were not suitable 
for detection. The last column indicates a maximum absorbance of the coated plant produced 
scFv, and indicates a significant difference to the background. 
The same N. benthamiana-produced scFv was used to probe an ELISA plate coated with the 
E. coli-produced 3B-O antigen at different dilutions (Figure 4.2 B). The scFv was able to 
significantly detect the antigen at both an undiluted and 1:2 dilution, but with the latter 
having a higher reading. The higher reading observed in the 1:2 dilution is also seen in Figure 
4.2A, further suggesting that this is the optimal dilution of the antigen. The 1:10 dilution gave 
a low reading similar to that of the background control. The maximum absorbance of the scFv 
again showed a significant difference to the background, as seen in the last column. 
The E. coli-produced scFv was also used to probe for the N. benthamiana-produced 3B-O 
antigen (Figure 4.2 C) as well as the E. coli-produced 3B-O antigen (Figure 4.2 D). The readings 
for all the antigen dilutions were not significantly different to that of the background control. 
However, the maximum scFv reading, shown in the last column, is significantly different to 
the background, indicating that the scFv is present, even though detected at very low levels 
in comparison to the N. benthamiana-expressed scFv maximum absorbance positive controls 
in Figure 4.2 A and B.  
A constant 1:3 dilution of the recombinant scFv from both E. coli and N. benthamiana was 
used in each of the ELISAs. It was suspected that the difference in activity between the 
differently expressed scFvs might be due to keeping the dilution of them the same and not 
using a constant concentration. To determine if the scFv from both E. coli and N. benthamiana 
varied in activity due to a concentration issue, a checker board titration was carried out. 
Whereby, varying dilutions of both expression systems of the 3B-O antigen were coated on 
an ELISA, and probed with varying concentrations of both expression systems of the scFv. It 
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was surmised that this would give an indication of the best ratio of antigen to scFv to be used. 
It was seen that the N. benthamiana-produced scFv was best used at a 1:3 dilution when 
detecting either plant or E. coli antigen at 107ng. The E. coli-produced scFv however did not 
give significant readings, even when an undiluted sample was used, in detecting either of the 
3B-O antigens (not shown). These results coincided with those seen in the I-ELISA in Figure 
4.2 and the western blots indicated that the E. coli-produced scFv is not effectively binding 
the antigen.  Therefore the N. benthamiana-expressed CRAb-FM27 scFv was taken forward 








(A) N. benthamiana-produced 3B-O coated and probed with N. benthamiana-produced scFv. (B) E. coli-produced 3B-O coated and probed 
with N. benthamiana-produced scFv. (C) N. benthamiana-produced 3B-O coated and probed with E. coli-produced scFv. (D) E. coli-produced 
3B-O coated and probed with E. coli-produced scFv. Antigen coated as undiluted, 1:2 and 1:10 dilutions. Background controls included 1:100 
dilutions of either N. benthamiana or E. coli empty vector crude extracts. Maximum scFv undiluted samples were coated and used as positive 
controls for presence of scFv. ScFv used at 1:3 dilution to probe for antigen and secondary anti-chicken alkaline phosphatase conjugate 
(1:5000) was used. The error bars indicate standard deviation with 95% confidence level and double asterisks (**) indicates P < 0.01 and 
quadruple asterisks (****) indicates P<0.0001. 
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4.3.3 I-ELISA TO TEST FOR THE PRESENCE OF ANTI-FMDV ANTIBODIES TOWARDS RECOMBINANT 3B-O. 
It is vital that antibodies from infected animal serum can recognise recombinantly produced 
3B-O antigen, for it to be considered a diagnostic candidate. Furthermore, for it to be 
considered as a possible DIVA diagnostic reagent, it would have to show that antibodies in 
animal serum from a vaccinated animal would not be able to be detected.   
To test the functionality of E. coli-produced and N. benthamiana-produced 3B-O antigens, an 
I-ELISA was carried out to determine whether the recombinant antigens could detect 
antibodies in serum from 6 different samples of FMDV-infected animals.  In addition, the 
recombinant antigens were tested to determine whether they could differentiate this serum 
from that of vaccinated animal serum. 
Purified recombinant 3B-O antigen, either N. benthamiana or E. coli-produced, was coated 
into microtiter plate wells.  The 6 different guinea pig serum samples containing antibodies 
representing 6 different FMDV serotypes and two subtypes (Table 4.1) were added to wells 
of the coated plates. Each row of the plate was designated one serum sample and each row 
consisted of a test sample (3B-O antigen from either N. benthamiana or E. coli), a background 
control (E. coli or N. benthamiana crude sample from an empty vector) and a positive control 
(3AB1 sample from INTA). The ability of the 3B-O protein to distinguish infected and 
vaccinated serum is critical, and therefore to one of the rows serum from a vaccinated animal 
was added (Table 4.1).  The statistical analysis of the data was done using an ordinary one-
way ANOVA test, which did a multiple comparison between the test samples and the 
backgrounds. 
Results from these experiments are shown in Figure 4.3. Absorbance values of background 
controls and test samples were compared and plotted next to each other for each serum 
sample tested. The E. coli-produced 3B-O tests showed to have significantly higher 
absorbance values to that of the background controls for each of the 6 infected sera tested 
(Figure 4.3A).  Serum sample O1 showed a lower absorbance value than the other 5 samples 
tested.  The E. coli-produced 3B-O showed similar absorbance values to that of the 
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background control for the C85 serum sample from a vaccinated animal, indicating that it did 
not bind to antibodies in the serum.   
The N. benthamiana-produced 3B-O tests showed significantly higher absorbance in 
comparison to the background controls of 5 of the 6 infected serum samples (Figure 4.3 B). 
The O1 serum sample showed a higher absorbance value for the test when compared to the 
background control but was not significant. The C85 vaccinated animal serum showed similar 
absorbance values between the N. benthamiana-produced 3B-O test and the plant 
background control, suggesting that antibodies in the serum do not recognise the 3B-O 
protein. 
For the E. coli-produced 3AB1 (Figure 4.3 C) there was a significant increase in the absorbance 
of the 6 serum samples between the 3AB1 test and E. coli background control. The O1 sample 
again had a lower reading than the other 5 samples but this was still significantly higher than 
the background. There was no significant difference in absorbance between the 3AB1 protein 
and the background control when testing the C85 vaccinated animal serum. These results 
confirm that infected and vaccinated serum was distinguishable with 95% confidence when 














(A) E. coli-produced 3B-O coated. (B) N. benthamiana-produced 3B-O coated. (C) 3AB1 protein coated as positive control. Solid 
bars indicate antigen being tested and gridded bar indicates background control, for each of the serum. Guinea pig serum used 
at 1:10 dilution and anti-Guinea pig alkaline phosphatase conjugate used at 1:10 000. The error bars indicate standard deviation 
with 95% confidence level and quadruple asterisks (****) indicate P<0.0001. 
91 
 
4.3.4 COMPETITIVE-ELISA TO TEST FUNCTIONALITY OF RECOMBINANT ANTIGEN AND SCFV IN THE PRESENCE OF 
FMDV ANTI-SERUM.  
The scFv produced in N. benthamiana could bind the 3B-O antigen (section 4.3.2), and the 3B-
O antigen produced in both E. coli and N. benthamiana was able to distinguish between serum 
from FMDV infected and vaccinated animals (section 4.3.3). With these results, an ELISA was 
carried out to determine whether these two reagents could be used together in a C-ELISA to 
differentiate between animal sera. 
The 3B-O antigen from both N. benthamiana and E. coli was coated in the wells of an ELISA 
plate and different dilutions of serum from infected guinea pigs added. N. benthamiana-
produced scFv was added to each of the wells at a final dilution of 1:3 and given a chance to 
compete with the antibodies for the binding of the 3B-O antigen, with further incubation. The 
E. coli crude samples containing the empty pProEX-HTb expression vector and N. 
benthamiana crude samples from leaves infiltrated with Agrobacterium containing plant 
expression vectors lacking the gene of interest, were again used as the background controls. 
E. coli and N. benthamiana –produced 3B-O antigen was coated as before, but with only the 
scFv added (without animal serum), to be used as a maximum absorbance control. The 
maximum absorbance reading was used to calculate the percentage of inhibition of the scFv 
in the test samples. 
The results for both the E. coli and N. benthamiana-produced 3B-O C-ELISAs were 
inconclusive, as all the samples tested gave similar readings to the background control. The 
absorbance values were very low and similar across the different dilutions of the 6 infected 
animal sera, which was the same seen for the vaccinated animal serum. The expected results, 
which would have shown a successful C-ELISA test, would have shown an increase of 
absorbance as the dilutions of the infected animal serum was increased (i.e. decreasing 
concentration of antibodies). It would also have shown a consistent high absorbance reading 
across the vaccinated serum dilutions. The maximum absorbance control showed a similar 
low absorbance reading to that of the background and other test samples. This control was 
used as a positive control to show maximum binding of scFv to the antigen to determine the 
percentage of inhibition when comparing absorbance readings against the test sample 
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readings. Therefore, it should have given a very high absorbance reading. The C-ELISA for both 
E. coli and N. benthamiana-produced 3B-O using the N. benthamiana-produced scFv was 
repeated in triplicate but each experiment gave similar results (not shown).      
4.4 DISCUSSION 
Production and purification of both the 3B-O antigen and CRAb-FM27 scFv was successful in 
both N. benthamiana and E. coli. The objective of the project was to produce functional 
proteins which could be used in combination with each other to distinguish between serum 
from FMDV-infected and vaccinated animals in a C-ELISA. 
In order for these proteins to be used for diagnostic purposes, they would each have to display 
specific characteristics. Firstly, the scFv would need to show specific antigen binding. This is 
of great importance, as the scFv must act as a competing antibody when used in a C-ELISA. 
The E. coli produced CRAb-FM27 scFv has been shown, by another research group, to bind 
the full length non-structural 3ABC polypeptide and more specifically the epitopes found on 
the 3B region (Foord et al., 2007). I wanted to test whether the plant produced CRAb-FM27 
scFv would behave similarly, and to determine if it could act as a possible diagnostic 
candidate. The initial testing of this interaction was done via a western blot, where the 3B-O 
antigen was probed using the recombinant scFv as an antibody, in order to give some idea of 
the binding capabilities of the scFv for the antigen.  
The results indicated that N. benthamiana-produced scFv was capable of detecting the E. coli-
produced 3B-O antigen as seen by a defined band on the western blot (Figure 4.1A). In 
addition, the E. coli 3B-O antigen was shown to be present and recognised by the anti-his 
antibody used as a positive control in a western blot (Figure 4.1 B). When comparing the 
western blots of the 3B-O protein either probed with the plant produced scFv or anti-his 
antibody, I saw the expected lower band (13KDa) in both, but only the higher band (≈20KDa) 
emerging in the anti-his blot. This double band was observed throughout the expression of 
3B-O in both E. coli and N. benthamiana (see results section 2.3.4.1 and 2.3.4.2) when 
analysed using an anti-his western blot. The disappearance of the upper (≈20KDa) band was 
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observed when using the N. benthamiana-produced scFv to probe the blot, and it was only 
the lower 13KDa band that was detected (Figure 4.1 A). It was surmised that the scFv was only 
able to detect the lower band and not the upper band of the 3B-O protein as the smaller 
molecular weight form of the protein is conformationally correct to allow for binding of the 
scFv. It has been hypothesised that the double band seen in the western blot of the 3B-O 
protein is due to one or more of the many types of post-translational modifications (PTMs) 
that take place within the cell (discussed in Chapter 2). The N-acetylation of lysine residues in 
proteins takes place within both prokaryotic and eukaryotic systems (Ouidir, Kentache and 
Hardouin, 2016) and is thought to influence the expression of the 3B-O protein such that two 
different conformations results in a change in sizes (Guan et al., 2010). The lower band 
(13KDa) is surmised to be the least post-translationally modified form of the protein as it is 
closest to the predicted size of the protein than the upper band (≈20KDa). This might explain 
why only the lower band is detected by the scFv, as the epitopes to which the scFv would 
bind, might be hidden by the extensive acetylation or other PTMs that are found in the larger 
(upper band) form of the protein.  
The detection of the N. benthamiana-produced 3B-O protein using the same N. benthamiana-
produced scFv was not as clear as in the E. coli western blot, as very faint protein bands were 
seen. The faint band seen was of the lower molecular weight protein. It has been 
hypothesised that due to the plant system (eukaryote) having an extensive secretary 
pathway, increased post-translational modification would occur in comparison to a bacterial 
system (prokaryote) (Dell et al., 2010). It was also noted that the plant expressed 3B-O 
produced a darker, more dense upper band than the lower one (Figure 2.8), suggesting 
increased concentrations which is possibly due to the increase in PTMs taking place. This 
might explain why the lower band of the plant made 3B-O antigen, shows such a faint band 
when probed with the scFv on a western blot, as there is very low concentrations of the lower 
form being present.  
Western blots probed with the E. coli-produced scFv did not show any binding to either the 
E. coli or N. benthamiana-produced 3B-O antigen. It is possible that the E. coli-produced scFv 
may therefore be non-functional in recognising the 3B-O antigen, as a result of less PTMs 
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taking place during E. coli expression (Frenzel, Hust and Schirrmann, 2013) compared to plant 
expression and hence, influencing and possibly reducing the activity of the scFv. This 
contradicts the evidence published by Foord et al. (2007), who showed that the E. coli-
expressed CRAb-FM27 scFv was able to detect the E. coli-produced antigens 3B and 3ABC on 
a western blot.  
Since results from the western blot were inconsistent with expectations, an ELISA was 
employed using combinations of these reagents. It was shown in an I-ELISA that the N. 
benthamiana-produced scFv could significantly detect the 3B-O antigen made from both N. 
benthamiana and E. coli (Figure 4.2 A&B respectively). However, the E. coli made scFv could 
not (Figure 4.3 C&D), which confirmed the non-functionality of the E. coli-produced scFv. 
Consequently, only the plant-produced scFv was employed for further work.  
The second characteristic to determine suitability of the reagents for diagnostic use, was to 
verify whether the 3B-O antigen could be recognised by antibodies from infected animal 
serum, but not antibodies from vaccinated animal serum. It has previously been shown that 
FMDV 3B can be used instead of the full length 3ABC polyprotein as a coating reagent in an 
ELISA in order to successfully distinguish infected from vaccinated animal serum (Shen et al., 
1999; Gao et al., 2012; Mohapatra et al., 2014).  
An indirect-ELISA was employed to distinguish infected and vaccinated guinea pig serum from 
three serotypes, each with two subtypes: serotype C (subtypes C85 and CC59), serotype A 
(subtype A24 and A87) and serotype O (subtype O1 and O1C) (Table 4.1). In order to show 
distinguishability of sera, serum from an animal sample vaccinated with FMDV C85 was used. 
Results showed that the 3B-O antigen produced in E. coli was detectable by antibodies from 
infected guinea pig serum for all serotypes and subtypes tested. The plant-produced 3B-O 
antigen showed similar results. Interestingly, the absorbance readings from each of the sera 
tested with plant-made 3B-O varied in comparison to the E. coli antigen tests as they were 
slightly higher, along with increased error bars. The difference in absorbance could be a result 
of antibody accessibility to the differently expressed antigens. It could also be due to higher 
titres of antibodies being present in the serum which recognise native plant proteins, which 
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have been co-purified with the plant-produced 3B-O, than there are antibodies towards the 
native E. coli proteins. There was a significant difference in absorbance readings between the 
plant background and plant produced 3B-O samples for each of the tested sera, except for 
the O1 subtype. This general trend of a lower absorbance reading for the O1 subtype sample 
seen in the plant made antigen test, the E. coli antigen test and as well as the positive control, 
could be due to the serum being old and therefore the antibodies losing binding activity 
(Correia, 2010). It could also mean that there was a lower titre of antibodies in that particular 
sample, which before gave a lower reading. 
Overall, I have shown that the N. benthamiana and E. coli-produced 3B-O antigen is 
significantly recognised by antibodies in serum from FMDV-infected samples, but not by 
antibodies in the serum sample from a vaccinated animal. This indicates the potential of the 
3B-O antigen, expressed from both systems, to be used as a diagnostic reagent for DIVA 
capacity. A limitation of this particular experiment is that there was only one vaccinated 
sample representing one subtype tested.  This experiment should be repeated with more sera 
isolated from vaccinated as well as from healthy unvaccinated animals in order to calculate 
significance.   
The N. benthamiana and E. coli-produced 3B-O was subsequently used in a C-ELISA, along 
with the N. benthamiana-produced CRAb-FM27 scFv to determine whether they were able to 
differentiate infected from vaccinated serum. The advantage of a C-ELISA is that only two 
common reagents are needed in order to test a range of samples that might come from 
different animal species. In this case, to determine which of the guinea pig serum has been 
infected or not, an ELISA plate is coated with the 3B-O antigen and the serum under 
investigation is added. To this, the plant made scFv would be added in order to compete with 
antibodies in the serum for the binding of the antigen. To determine which of the animals is 
infected, only a single secondary conjugate antibody (anti-chicken in this case) is needed, 
which would detect the scFv and determine the infectious status of the animal. This alleviates 
the need for specific or multiple secondary antibodies towards antibodies of the animal 
suspected to be infected (i.e. anti-guinea pig conjugate). The lack in scFv detection (i.e. low 
absorbance readings) would indicate an infected sample, as the scFv has been outcompeted 
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by antibodies, raised against live replicating virus. Whereas detection of the scFv (i.e. high 
absorbance readings) would indicate a lack of binding antibodies and that the animal has been 
vaccinated or is healthy.  
C-ELISAs were conducted using either the plant or E. coli made 3B-O antigen as a coating 
antigen to select for specific NSP antibodies (i.e. those found in sera from infected animals), 
and plant-produced scFv as the competing antibody. Unfortunately, the results were 
inconclusive for both, as the infected serum samples gave very low absorbance readings in all 
three replicates (not shown). The low absorbance readings in the infected samples was to be 
expected; however, the vaccinated sample should have shown a high absorbance reading if 
the C-ELISA had worked, but had given similar readings to the infected samples. The positive 
control also showed low absorbance readings, when it should have shown maximum 
absorbance readings.  The very low level of absorbance observed in the positive control 
suggests that there is an underlying problem with the interaction between the scFv and the 
3B-O antigen, as the lack of raised absorbance indicates no or very little binding between 
these two reagents.  This is contradictory to results obtained with the I-ELISAs which showed 
that the scFv was able to bind to 3B-O. The only differences between these experiments was 
1) that the scFv showed binding to the antigen in the absence of the serum but a lack of 
binding in its presence. 2) The scFv used in the C-ELISA was purified from a new batch of 
plants, but processed in the same way. An explanation to why the C-ELISA was unsuccessful 
could be due to the scFv being inhibited by an unknown molecule found within the serum, or 
that the new batch of scFv was non-functional due to it not reacting to the antigen alone in 
the maximum absorbance control.  
Optimisation of the C-ELISA could not be fully explored due to time constraints. There are still 
many avenues to be explored in order to certify these proteins as diagnostic reagents. 
Therefore, future work would include a complete repeat of antigen and scFv expression in the 
successful expression systems. Once sufficient quantities of each protein are obtained, testing 
using multiple experimental conditions could be done. There are many types of coating, 
blocking, and wash buffers for ELISAs that would need to be tested. There are a range of 
different ELISAs that could be tested to determine which might be most effective (e.g. 
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capture-ELISA to better expose the antigen). Titrations of the antigens and scFv to find the 
optimal working concentration of each, and a possible titration of the animal serum in order 
to determine the best dilution to be used in a C-ELISA could also be done.  
CHAPTER 5 
CONCLUSION 
The diagnosis of FMDV disease employs three different approaches: these are clinical, 
virological and serological testing. The clinical approach relies largely on symptomatic 
inspection of the animals. This is often challenging as other viruses and other disease agents 
are known to cause similar or even identical symptoms. Consequently, by the time the animal 
has been identified as FMDV-infected by symptomatic criteria, the virus has probably already 
spread. Thus, clinical analysis is often combined with a more thorough or more specific 
approach of diagnosis. This includes virological and serological testing of animal tissue or 
fluids. The virological method of diagnosis includes virus isolation and/or direct detection of 
viral structural proteins or viral nucleic acid. This manner of diagnosis is usually expensive and 
time consuming and requires high levels of biosafety for live virus handling. Serological 
methods include identification of binding and/or antibodies in animal serum using both the 
structural (SP) and non-structural (NSP) viral proteins. These methods generally use ELISA-
based techniques which can distinguish between different serotype infections using binding 
of antibodies from animal sera to structural proteins such as the VP1, or determine if the 
animal has been infected or vaccinated by use of non-structural proteins such as 3B or 3ABC 
polyproteins. The use of ELISAs, with either SPs or NSPs, is found to be the most inexpensive 
and generally the most rapid form of diagnosis. 
A country or region that is considered FMDV-free without the use of vaccinations, would use 
SP-based ELISA testing in order to detect infection. Complications arise when vaccinations are 
used as a form of protection and for mitigation of outbreaks. Countries where FMDV is 
endemic often use prophylactic vaccines to protect high value animals, whereas countries 
that are FMDV-free often use the same vaccines for outbreak control. If SP-ELISAs are used 
for diagnosis in this case, vaccinated animals can be mis-identified as being infected (false 
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positives), resulting in unnecessary culling. In order to prevent false positives, NSP-ELISAs are 
employed which have the ability to distinguish between infected and vaccinated animals.  
Although South Africa is currently classified as a FMDV-free zone, the Kruger National Park 
(KNP) is considered an infected zone within the country. To retain FMDV-free status, South 
Africa has isolated the KNP to prevent the spread of the virus from wild animals to livestock 
near its borders. Control zones have been implemented around the park in order to monitor 
the livestock in close proximity to the infected zone. Monitoring of livestock involves the 
utilisation of a range of diagnostics; however, due to vaccines being used to mitigate 
outbreaks, NSP-ELISAs are largely utilised. The continuous screening of large amounts of 
animal serum samples becomes expensive, and therefore the development of cheaper 
reagents to be used in these ELISA kits could reduce this financial burden, and potentially 
widen the scale of testing. 
This project’s focus was using transient plant expression for the production of FMDV 
diagnostic reagents. Plant expression has been shown to be an effective, safer and cheaper 
alternative to many other recombinant expression systems for the production of recombinant 
proteins. The use of a competitive-ELISA could reduce the cost of diagnostic testing as fewer 
reagents are needed in order to screen samples from multiple species. This work looked at 
the expression of plant-produced non-structural FMDV proteins and their functionality when 
used in combination with a plant-produced scFv antibody in a C-ELISA. 
The NSPs investigated were the full length FMDV 3ABC polypeptide from both serotype O and 
serotype A of the virus. The 3AB polyprotein from serotype O was also investigated, along 
with the 3AB1 polyprotein from serotype A and the 3B region from serotype O. These proteins 
are highly conserved amongst FMDV serotypes, which makes them excellent candidates for a 
broad range diagnostic system that can distinguish infected from vaccinated animals, across 
a wide range of serotypes.    
The expression of these NSPs was explored in a plant system as recombinant proteins 
produced in this manner are potentially easier and more cost effective to produce than using 
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the conventional bacterial or insect cells expression systems. Amongst the five variations of 
the non-structural polypeptides tested, the 3B-O protein was successfully expressed and 
purified from N. benthamiana leaves. To our knowledge this is the first time that a non-
structural portion of the FMDV viral genome has been expressed in plants. In order to have a 
point of reference for comparison of plant expression, the 3B-O protein was also successfully 
expressed and purified in an E. coli system. Both N. benthamiana and E. coli-produced 3B-O 
proteins were then tested in an indirect-ELISA in order to determine if they could differentiate 
between antiserum from FMDV-infected and -vaccinated guinea pigs. Results indicated that 
the 3B-O proteins produced from both expression systems were able to distinguish between 
serum from vaccinated and infected animals; this was from guinea pigs infected with a range 
of FMDV serotypes – namely, A, O and C. These results confirm that recombinant 3B-O protein 
produced in plants has the potential to be a highly suitable diagnostic candidate for ELISA. 
The second diagnostic reagent needed for C-ELISAs is a competing antibody that will bind the 
FMDV-NSP (3B-O) used to coat the ELISA plate. Foord et al. (2007) reported the identification 
of a single chain variable fragment (scFv), termed chicken recombinant antibody-Foot-and-
Mouth 27 (CRAb-FM27), which recognised epitopes on the 3B region of the FMDV 3ABC 
polypeptide. They successfully expressed both the 3ABC antigen and the scFv in an E. coli 
system and showed that these two reagents worked in combination with each other in a C-
ELISA to distinguish FMDV-infected serum from vaccinated serum.  
In this project I tested the expression of the CRAb-FM27 scFv in a plant system to further 
reduce the cost of production. The scFv was both successfully expressed and purified from N. 
benthamiana.  This is the first report of expression of this specific scFv (CRAb-FM27) in plants. 
The scFv was also concurrently successfully expressed and purified in an E. coli system, to 
serve as a control and a reference for future experiments. The functionality of the scFv was 
tested in order to see if it could bind its target protein. The plant-produced scFv showed 
binding activity towards both the N. benthamiana and E. coli-produced 3B-O protein in both 
a western blot and in an I-ELISA. However, the E. coli-produced scFv did not bind to the plant 
or the E. coli-expressed 3B-O protein, which is contrary to the findings of Foord et al. (2007).  
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The combined use of the two plant-produced reagents (3B-O and CRAb-FM27) was tested in 
a C-ELISA in order to determine if they could distinguish between sera from FMDV-infected 
and vaccinated guinea pigs. Despite the experiment being repeated three times, the C-ELISA 
was unsuccessful in that CRAb-FM27 did not bind to 3B-O.  Furthermore, the positive control 
(CRAb-FM27 added to 3B-O with no test serum) was negative. This indicates that there is an 
underlying issue with the scFv not effectively binding the 3B-O protein, which is contrary to 
what was shown when testing the interaction between the scFv and 3B-O antigen in an I-
ELISA. This disparity in results suggests that further work is needed in optimising C-ELISA 
conditions. Titrations for both the scFv and animal serum need to be optimised to improve 
the binding capabilities of the scFv to the antigen. The application of a capture-ELISA might 
be useful in presenting the antigen more effectively, and hence further exposing the epitopes 
for the scFv to bind. Unfortunately, these optimisation steps were not explored due to time 
constraints. 
Future work could include additional experimentation of the NSP expression with different 
plant vectors (e.g. pEAQ-HT, deconstructed viral vectors). This would be to determine if the 
other NSPs (3ABC-O, 3AB-O and 3AB1-Arg), which were not successfully expressed using the 
pRIC3.0-HT or pTRAKc vectors, could be produced in plants. In addition, these NSPs could be 
targeted and retained within other plant subcellular compartments, for example the ER or 
chloroplast, in order to reduced proteolysis and increase protein levels. The expression of 
many recombinant proteins in plants is limited by host gene silencing. The use of a gene 
silencing suppressor, for example P19, could be explored to enhance the expression of the 
NSPs. Screening for an alternative antibody or scFv for antigen detection could be explored 
using phage display scFv libraries newly available in the BRU, where a range of candidates 
could be generated from a library using the plant-produced NSP for screening purposes. This 
would help possibly identify more sensitive and specific scFvs, which could be used in a C-
ELISA, for the competitive binding towards the plant produced antigens. If other competing 
antibodies or scFvs were to be identified for binding to the NSPs, they could be recombinantly 
expressed along with an enzyme (e.g. alkaline phosphatase or horseradish peroxidase) fused 
to it – technology that is also available in the BRU. This could generate a competing reagent 
that would function independently without the need for a secondary antibody for detection.  
Subsequently, a secondary conjugated antibody would not be necessary to detect the primary 
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antibody or competing agent in the ELISA. Therefore, the recombinant competing antibody 
or scFv would be directly detectable using the appropriate substrate, further making this a 
more affordable method of diagnosis.  
In conclusion, the individual reagents for a C-ELISA were successfully expressed in plants and 
showed appropriate functionality in an I-ELISA, although not in a C-ELISA.  This provides proof 
of concept that both functional antigens and their cognate scFvs can be made in plants, 
thereby providing a more cost-effective platform for production of candidate diagnostic 
FMDV reagents.  
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